| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
22 Dec 2025 |
22 Dec 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ENHERTU GRANTED BTD FOR POST-NEOADJUVANT EARLY BC |
22 Dec 2025 |
22 Dec 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
UPDATE ON LATIFY PHASE III TRIAL OF CERALASERTIB |
22 Dec 2025 |
22 Dec 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
19 Dec 2025 |
19 Dec 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
SUBCUTANEOUS SAPHNELO APPROVED IN EU |
16 Dec 2025 |
16 Dec 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ENHERTU APPROVED IN US FOR 1L HER2+ METASTATIC BC |
16 Dec 2025 |
16 Dec 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
HOLDING(S) IN COMPANY |
04 Dec 2025 |
04 Dec 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
BLOCK LISTING INTERIM REVIEW |
01 Dec 2025 |
01 Dec 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Dec 2025 |
01 Dec 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
IMFINZI APPROVED IN US FOR EARLY GASTRIC CANCER |
26 Nov 2025 |
26 Nov 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA MANUFACTURING INVESTMENT IN MARYLAND |
24 Nov 2025 |
24 Nov 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
KOSELUGO (SELUMETINIB) APPROVED IN THE US |
20 Nov 2025 |
20 Nov 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
HOLDING(S) IN COMPANY |
17 Nov 2025 |
17 Nov 2025 |
001-11960 |
| 25-NSE |
Open Document
|
Open Filing |
|
14 Nov 2025 |
|
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
14 Nov 2025 |
14 Nov 2025 |
001-11960 |
| 144 |
Open Document
|
Open Filing |
|
12 Nov 2025 |
|
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
10 Nov 2025 |
10 Nov 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
9M AND Q3 2025 RESULTS |
06 Nov 2025 |
06 Nov 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
RESULT OF GENERAL MEETING |
03 Nov 2025 |
03 Nov 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
03 Nov 2025 |
03 Nov 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FORM 6-K |
03 Nov 2025 |
03 Nov 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR DECLARATION |
28 Oct 2025 |
28 Oct 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
KOSELUGO (SELUMETINIB) APPROVED IN THE EU |
28 Oct 2025 |
28 Oct 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TEZSPIRE APPROVED IN EU FOR CRSWNP |
22 Oct 2025 |
22 Oct 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
US FDA APPROVES TEZSPIRE IN CRSWNP |
20 Oct 2025 |
20 Oct 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
POSITIVE CHMP OPINION FOR SUBCUTANEOUS SAPHNELO |
20 Oct 2025 |
20 Oct 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
AGREEMENT WITH US GOVT TO LOWER MEDICINE PRICES |
14 Oct 2025 |
14 Oct 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
BAXDROSTAT MET PRIMARY ENDPOINT IN BAX24 PH3 TRIAL |
07 Oct 2025 |
07 Oct 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DATROWAY IMPROVED OS AND PFS IN TROPION-BREAST02 |
06 Oct 2025 |
06 Oct 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Oct 2025 |
01 Oct 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ENHERTU IMPROVED IDFS IN EARLY BC IN DB-05 |
29 Sep 2025 |
29 Sep 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
AZN HARMONISES LISTING STRUCTURE |
29 Sep 2025 |
29 Sep 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
6-K |
29 Sep 2025 |
29 Sep 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
25 Sep 2025 |
25 Sep 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
KOSELUGO RECOMMENDED FOR EU APPROVAL |
22 Sep 2025 |
22 Sep 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TEZSPIRE RECOMMENDED FOR APPROVAL IN EU FOR CRSWNP |
22 Sep 2025 |
22 Sep 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
SAPHNELO MET PRIMARY ENDPOINT IN TULIP-SC |
17 Sep 2025 |
17 Sep 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
UPDATE ON RESOLUTE PHASE III TRIAL |
17 Sep 2025 |
17 Sep 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
02 Sep 2025 |
02 Sep 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
HOLDING(S) IN COMPANY |
28 Aug 2025 |
28 Aug 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
HOLDING(S) IN COMPANY |
26 Aug 2025 |
26 Aug 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
HOLDING(S) IN COMPANY |
21 Aug 2025 |
21 Aug 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
18 Aug 2025 |
18 Aug 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
HOLDING(S) IN COMPANY |
15 Aug 2025 |
15 Aug 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
HOLDING(S) IN COMPANY |
12 Aug 2025 |
12 Aug 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Aug 2025 |
01 Aug 2025 |
001-11960 |
| 6-K |
Open Document
| Data
|
Open Filing |
FORM 6-K |
29 Jul 2025 |
30 Jun 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
GEFURULIMAB NANOBODY MET PHASE III ENDPOINTS |
24 Jul 2025 |
24 Jul 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA PLANS TO INVEST $50BN IN THE US |
22 Jul 2025 |
22 Jul 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
UPDATE ON ANSELAMIMAB IN AL AMYLOIDOSIS |
16 Jul 2025 |
16 Jul 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
BAXDROSTAT MET PRIMARY ENDPT IN BAXHTN PHIII TRIAL |
14 Jul 2025 |
14 Jul 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
IMFINZI APPROVED IN THE EU FOR BLADDER CANCER |
07 Jul 2025 |
07 Jul 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Jul 2025 |
01 Jul 2025 |
001-11960 |
| 11-K |
Open Document
|
Open Filing |
FORM 11-K |
26 Jun 2025 |
31 Dec 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DATROWAY APPROVED IN US FOR EGFRM LUNG CANCER |
24 Jun 2025 |
24 Jun 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA ENTERS INTO COLLABORATION WITH CSPC |
13 Jun 2025 |
13 Jun 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
12 Jun 2025 |
12 Jun 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FIXED-DURATION CALQUENCE APPROVED IN EU FOR 1L CLL |
06 Jun 2025 |
06 Jun 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
BLOCK LISTING INTERIM REVIEW |
02 Jun 2025 |
02 Jun 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
02 Jun 2025 |
02 Jun 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
IMFINZI RECOMMENDED IN EU FOR BLADDER CANCER |
27 May 2025 |
27 May 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
23 May 2025 |
23 May 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR DECLARATION |
21 May 2025 |
21 May 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ACQUISITION OF ESOBIOTEC COMPLETED |
20 May 2025 |
20 May 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
IMFINZI IMPROVED DFS IN EARLY BLADDER CANCER |
09 May 2025 |
09 May 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ENHERTU IMPROVED PCR IN EARLY-STAGE BREAST CANCER |
07 May 2025 |
07 May 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
CALQUENCE COMBINATION APPROVED IN EU FOR 1L MCL |
06 May 2025 |
06 May 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
BREZTRI MET PRIMARY ENDPOINTS IN PH3 ASTHMA TRIALS |
02 May 2025 |
02 May 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
01 May 2025 |
01 May 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 May 2025 |
01 May 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FIXED-DURATION CALQUENCE RECOMMENDED IN EU FOR CLL |
29 Apr 2025 |
29 Apr 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
UPDATE ON CAPITELLO-280 PHASE III TRIAL |
29 Apr 2025 |
29 Apr 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
1ST QUARTER RESULTS |
29 Apr 2025 |
29 Apr 2025 |
001-11960 |
| SCHEDULE 13G/A |
Open Document
|
Open Filing |
|
23 Apr 2025 |
|
005-55247 |
| 6-K |
Open Document
|
Open Filing |
ENHERTU COMBINATION IMPROVED PFS IN 1L HER2+ MBC |
22 Apr 2025 |
22 Apr 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
RESULT OF AGM |
11 Apr 2025 |
11 Apr 2025 |
001-11960 |
| SCHEDULE 13G/A |
Open Document
|
Open Filing |
|
10 Apr 2025 |
|
|
| 6-K |
Open Document
|
Open Filing |
IMFINZI APPROVED IN EU FOR AEGEAN |
04 Apr 2025 |
04 Apr 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ENHERTU APPROVED IN EU IN POST-ET BREAST CANCER |
04 Apr 2025 |
04 Apr 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Apr 2025 |
01 Apr 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
CALQUENCE RECOMMENDED FOR EU APPROVAL IN 1L MCL |
31 Mar 2025 |
31 Mar 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
IMFINZI APPROVED IN THE US FOR BLADDER CANCER |
31 Mar 2025 |
31 Mar 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
AZN INVESTS $2.5BN IN BEIJING R&D & MANUFACTURING |
21 Mar 2025 |
21 Mar 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ENEBOPARATIDE PHASE III TRIAL MET PRIMARY ENDPOINT |
17 Mar 2025 |
17 Mar 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
IMFINZI APPROVED IN EU FOR LIMITED-STAGE SCLC |
17 Mar 2025 |
17 Mar 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA TO ACQUIRE ESOBIOTEC |
17 Mar 2025 |
17 Mar 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
HOLDING(S) IN COMPANY |
12 Mar 2025 |
12 Mar 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
07 Mar 2025 |
07 Mar 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
NOTICE OF AGM |
07 Mar 2025 |
07 Mar 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
IMFINZI IMPROVED EFS IN EARLY-STAGE GASTRIC CANCER |
07 Mar 2025 |
07 Mar 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FORM 6-K |
07 Mar 2025 |
07 Mar 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
06 Mar 2025 |
06 Mar 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
05 Mar 2025 |
05 Mar 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
03 Mar 2025 |
03 Mar 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
IMFINZI RECOMMENDED FOR EU APPROVAL FOR AEGEAN |
03 Mar 2025 |
03 Mar 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ENHERTU RECOMMENDED IN EU IN POST-ET BREAST CANCER |
28 Feb 2025 |
28 Feb 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
CAMIZESTRANT IMPROVED PFS IN 1L HR+ BREAST CANCER |
26 Feb 2025 |
26 Feb 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FILING OF FORM 20-F WITH SEC |
19 Feb 2025 |
19 Feb 2025 |
001-11960 |
| IRANNOTICE |
Open Document
|
Open Filing |
IRANNOTICE |
18 Feb 2025 |
|
001-11960 |
| 20-F |
Open Document
| Data
|
Open Filing |
FORM 20-F |
18 Feb 2025 |
31 Dec 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FORM 6-K |
18 Feb 2025 |
18 Feb 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
HOLDING(S) IN COMPANY |
18 Feb 2025 |
18 Feb 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ANNUAL FINANCIAL REPORT |
18 Feb 2025 |
18 Feb 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTORATE CHANGE |
18 Feb 2025 |
18 Feb 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FINAL RESULTS |
06 Feb 2025 |
06 Feb 2025 |
001-11960 |
| EFFECT |
Open Document
|
Open Filing |
|
05 Feb 2025 |
|
333-284374 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
03 Feb 2025 |
03 Feb 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
IMFINZI RECOMMENDED FOR EU APPROVAL FOR LS-SCLC |
03 Feb 2025 |
03 Feb 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ENHERTU APPROVED IN US FOR BREAST CANCER POST ET |
28 Jan 2025 |
28 Jan 2025 |
001-11960 |
| SCHEDULE 13D/A |
Open Document
|
Open Filing |
|
24 Jan 2025 |
|
|
| F-6 |
Open Document
|
Open Filing |
|
21 Jan 2025 |
|
333-284374 |
| 6-K |
Open Document
|
Open Filing |
DATO-DXD APPROVED IN US FOR HR+ BREAST CANCER |
21 Jan 2025 |
21 Jan 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
CALQUENCE COMBINATION APPROVED IN US FOR 1L MCL |
17 Jan 2025 |
17 Jan 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
02 Jan 2025 |
02 Jan 2025 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DATO-DXD NSQ NSCLC APPLICATION WITHDRAWN IN EU |
26 Dec 2024 |
26 Dec 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TAGRISSO APPROVED IN EU BASED ON LAURA TRIAL |
23 Dec 2024 |
23 Dec 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTORATE CHANGE |
16 Dec 2024 |
16 Dec 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
IMFINZI APPROVED IN US FOR LIMITED-STAGE SCLC |
05 Dec 2024 |
05 Dec 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA APPOINTS ISKRA REIC EVP INTERNATIONAL |
04 Dec 2024 |
04 Dec 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
BLOCK LISTING INTERIM REVIEW |
02 Dec 2024 |
02 Dec 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
02 Dec 2024 |
02 Dec 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TRUQAP IMPROVED RPFS IN ADVANCED PROSTATE CANCER |
25 Nov 2024 |
25 Nov 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
20 Nov 2024 |
20 Nov 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TAGRISSO RECOMMENDED FOR EU APPROVAL - LAURA |
18 Nov 2024 |
18 Nov 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
15 Nov 2024 |
15 Nov 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
15 Nov 2024 |
15 Nov 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
13 Nov 2024 |
13 Nov 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA INVESTS $3.5 BILLION IN US |
12 Nov 2024 |
12 Nov 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
KOMET PHASE III TRIAL MET PRIMARY ENDPOINT |
12 Nov 2024 |
12 Nov 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
9M AND Q3 2024 RESULTS |
12 Nov 2024 |
12 Nov 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DATO-DXD NEW BLA SUBMITTED, NSQ BLA WITHDRAWN |
12 Nov 2024 |
12 Nov 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TEZSPIRE NASAL POLYPS TRIAL MET PRIMARY ENDPOINTS |
08 Nov 2024 |
08 Nov 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Nov 2024 |
01 Nov 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
AZN CHINA PRESIDENT UNDER INVESTIGATION |
30 Oct 2024 |
30 Oct 2024 |
001-11960 |
| SC 13G |
Open Document
|
Open Filing |
SC 13G |
28 Oct 2024 |
|
|
| 6-K |
Open Document
|
Open Filing |
FORM 6-K |
21 Oct 2024 |
21 Oct 2024 |
001-11960 |
| SC 13G |
Open Document
|
Open Filing |
SC 13G |
11 Oct 2024 |
|
|
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA LICENSES LIPID LOWERING LP(A) ASSET |
07 Oct 2024 |
07 Oct 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Oct 2024 |
01 Oct 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TAGRISSO US APPROVAL IN UNRESECTABLE LUNG CANCER |
26 Sep 2024 |
26 Sep 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FASENRA RECOMMENDED FOR EU APPROVAL IN EGPA |
23 Sep 2024 |
23 Sep 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FINAL OS RESULTS REPORTED FOR TROPION - BREAST01 |
23 Sep 2024 |
23 Sep 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FLUMIST APPROVED FOR SELF-ADMINISTRATION IN US |
20 Sep 2024 |
20 Sep 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FASENRA EGPA US FDA APPROVAL |
18 Sep 2024 |
18 Sep 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
13 Sep 2024 |
13 Sep 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
03 Sep 2024 |
02 Sep 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
IMFINZI APPROVED IN US FOR RESECTABLE LUNG CANCER |
16 Aug 2024 |
16 Aug 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Aug 2024 |
01 Aug 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA PRICES A EUR1.4BN BOND OFFERING |
30 Jul 2024 |
30 Jul 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
CALQUENCE FIXED-DURATION COMBO IMPROVED 1L CLL PFS |
29 Jul 2024 |
29 Jul 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ODAC REVIEWED IMFINZI IN RESECTABLE LUNG CANCER |
26 Jul 2024 |
26 Jul 2024 |
001-11960 |
| 6-K |
Open Document
| Data
|
Open Filing |
FORM 6K |
25 Jul 2024 |
30 Jun 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ACQUISITION OF AMOLYT PHARMA COMPLETED |
15 Jul 2024 |
15 Jul 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Jul 2024 |
01 Jul 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
LYNPARZA & IMFINZI POSITIVE CHMP IN ENDOMETRIAL |
01 Jul 2024 |
01 Jul 2024 |
001-11960 |
| 11-K |
Open Document
|
Open Filing |
ANNUAL REPORT |
26 Jun 2024 |
31 Dec 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
UPDATE ON IMFINZI ADJUVANT BR.31 TRIAL |
25 Jun 2024 |
25 Jun 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
IMFINZI IMPROVED EFS AND OS IN BLADDER CANCER |
25 Jun 2024 |
25 Jun 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
UPDATE ON CAPITELLO-290 PHASE III TRIAL |
18 Jun 2024 |
18 Jun 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
IMFINZI APPROVED IN THE US FOR ENDOMETRIAL CANCER |
17 Jun 2024 |
17 Jun 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
12 Jun 2024 |
12 Jun 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FORM 6-K |
04 Jun 2024 |
04 Jun 2024 |
001-11960 |
| 25-NSE |
Open Document
|
Open Filing |
|
04 Jun 2024 |
|
001-11960 |
| 6-K |
Open Document
|
Open Filing |
BLOCK LISTING INTERIM REVIEW |
03 Jun 2024 |
03 Jun 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
03 Jun 2024 |
03 Jun 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TAGRISSO PLUS CHEMO RECOMMENDED FOR APPROVAL IN EU |
03 Jun 2024 |
03 Jun 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DATO-DXD IMPROVED OS IN NONSQUAMOUS LUNG CANCER |
28 May 2024 |
28 May 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA TO DELIVER $80BN REVENUE BY 2030 |
21 May 2024 |
21 May 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA TO MANUFACTURE ADCS IN SINGAPORE |
20 May 2024 |
20 May 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
SUPERNOVA TRIAL MET COVID-19 PREVENTION ENDPOINT |
16 May 2024 |
16 May 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
15 May 2024 |
15 May 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA COMPLETES CELLECTIS EQUITY INVESTMENT |
07 May 2024 |
07 May 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
CALQUENCE COMBINATION IMPROVED PFS IN 1L MCL |
02 May 2024 |
02 May 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 May 2024 |
01 May 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TRUQAP RECOMMENDED FOR EU BREAST CANCER APPROVAL |
29 Apr 2024 |
29 Apr 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ENHERTU IMPROVED PFS IN HER2-LOW AND ULTRALOW |
29 Apr 2024 |
29 Apr 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
1ST QUARTER RESULTS |
25 Apr 2024 |
25 Apr 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
RESULT OF AGM |
11 Apr 2024 |
11 Apr 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA INCREASES 2024 DIVIDEND BY 7% |
11 Apr 2024 |
11 Apr 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ENHERTU APPROVED IN US FOR HER2+ SOLID TUMOURS |
08 Apr 2024 |
08 Apr 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
IMFINZI IMPROVED OS & PFS IN LIMITED-STAGE SCLC |
05 Apr 2024 |
05 Apr 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
02 Apr 2024 |
02 Apr 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
VOYDEYA APPROVED IN US |
02 Apr 2024 |
02 Apr 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FDA ACCEPTS DATO-DXD BLA FOR BREAST CANCER |
02 Apr 2024 |
02 Apr 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ULTOMIRIS APPROVED IN THE US FOR NMOSD |
25 Mar 2024 |
25 Mar 2024 |
001-11960 |
| DFAN14A |
Open Document
|
Open Filing |
DFAN14A |
19 Mar 2024 |
|
|
| F-3ASR |
Open Document
|
Open Filing |
F-3ASR |
19 Mar 2024 |
|
333-278067 |
| 6-K |
Open Document
|
Open Filing |
FORM 6-K |
19 Mar 2024 |
19 Mar 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA TO ACQUIRE AMOLYT |
14 Mar 2024 |
14 Mar 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
12 Mar 2024 |
12 Mar 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FORM 6-K |
07 Mar 2024 |
07 Mar 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
NOTICE OF AGM |
07 Mar 2024 |
07 Mar 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
06 Mar 2024 |
06 Mar 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
06 Mar 2024 |
06 Mar 2024 |
001-11960 |
| CERT |
Open Document
|
Open Filing |
|
06 Mar 2024 |
|
001-11960 |
| 8-A12B |
Open Document
|
Open Filing |
8-A12B |
05 Mar 2024 |
|
001-11960 |
| 6-K |
Open Document
|
Open Filing |
EMA VALIDATES DATO-DXD MAAS FOR NSQ NSCLC AND BC |
04 Mar 2024 |
04 Mar 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Mar 2024 |
01 Mar 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FORM 6-K |
26 Feb 2024 |
26 Feb 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
VOYDEYA RECOMMENDED FOR EU APPROVAL |
26 Feb 2024 |
26 Feb 2024 |
001-11960 |
| 424B2 |
Open Document
|
Open Filing |
424B2 |
23 Feb 2024 |
|
333-256406 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA PRICES A $5BN BOND OFFERING |
22 Feb 2024 |
22 Feb 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FORM 6-K |
22 Feb 2024 |
22 Feb 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
22 Feb 2024 |
22 Feb 2024 |
001-11960 |
| FWP |
Open Document
|
Open Filing |
FWP |
22 Feb 2024 |
|
333-256406 |
| SC TO-T/A |
Open Document
|
Open Filing |
SC TO-T/A |
21 Feb 2024 |
|
|
| 424B2 |
Open Document
|
Open Filing |
424B2 |
21 Feb 2024 |
|
333-256406 |
| 6-K |
Open Document
|
Open Filing |
FILING OF FORM 20-F WITH SEC |
21 Feb 2024 |
21 Feb 2024 |
001-11960 |
| S-8 |
Open Document
|
Open Filing |
FORM S-8 |
20 Feb 2024 |
|
333-277197 |
| IRANNOTICE |
Open Document
|
Open Filing |
IRANNOTICE |
20 Feb 2024 |
|
001-11960 |
| 20-F |
Open Document
| Data
|
Open Filing |
FORM 20-F |
20 Feb 2024 |
31 Dec 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FORM 6-K |
20 Feb 2024 |
20 Feb 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ANNUAL FINANCIAL REPORT |
20 Feb 2024 |
20 Feb 2024 |
001-11960 |
| SC TO-T/A |
Open Document
|
Open Filing |
SC TO-T/A |
20 Feb 2024 |
|
|
| 6-K |
Open Document
|
Open Filing |
FORM 6-K |
20 Feb 2024 |
20 Feb 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA COMPLETES ACQUISITION OF ICOSAVAX |
20 Feb 2024 |
20 Feb 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TAGRISSO PLUS CHEMO APPROVED IN US FOR LUNG CANCER |
20 Feb 2024 |
20 Feb 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FDA ACCEPTS DATO-DXD BLA FOR NONSQUAMOUS NSCLC |
20 Feb 2024 |
20 Feb 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TAGRISSO IMPROVED PFS IN STAGE III LUNG CANCER |
20 Feb 2024 |
19 Feb 2024 |
001-11960 |
| SC TO-T/A |
Open Document
|
Open Filing |
SC TO-T/A |
15 Feb 2024 |
|
|
| SC 13G/A |
Open Document
|
Open Filing |
SC 13G/A |
12 Feb 2024 |
|
|
| 6-K |
Open Document
|
Open Filing |
FINAL RESULTS |
08 Feb 2024 |
08 Feb 2024 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Feb 2024 |
01 Feb 2024 |
001-11960 |
| SC 13G/A |
Open Document
|
Open Filing |
|
24 Jan 2024 |
|
005-55247 |
| SC TO-T/A |
Open Document
|
Open Filing |
SC TO-T/A |
19 Jan 2024 |
|
|
| 6-K |
Open Document
|
Open Filing |
FORM 6-K |
19 Jan 2024 |
19 Jan 2024 |
001-11960 |
| SC TO-T/A |
Open Document
|
Open Filing |
SC TO-T/A |
11 Jan 2024 |
|
|
| CORRESP |
Open Document
|
Open Filing |
|
10 Jan 2024 |
|
|
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
02 Jan 2024 |
02 Jan 2024 |
001-11960 |
| SC TO-T |
Open Document
|
Open Filing |
SC TO-T |
27 Dec 2023 |
|
|
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA ACQUIRES GRACELL |
27 Dec 2023 |
27 Dec 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FORM 6-K |
26 Dec 2023 |
26 Dec 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
WAINUA (EPLONTERSEN) GRANTED FIRST US FDA APPROVAL |
22 Dec 2023 |
22 Dec 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
14 Dec 2023 |
14 Dec 2023 |
001-11960 |
| SC TO-C |
Open Document
|
Open Filing |
SC TO-C |
12 Dec 2023 |
|
|
| 6-K |
Open Document
|
Open Filing |
FORM 6-K |
12 Dec 2023 |
12 Dec 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA TO ACQUIRE ICOSAVAX |
12 Dec 2023 |
12 Dec 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
BLOCK LISTING INTERIM REVIEW |
01 Dec 2023 |
01 Dec 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Dec 2023 |
01 Dec 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DISCONTINUATION OF TWO CRYSTALIZE EVIDENCE TRIALS |
01 Dec 2023 |
01 Dec 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
24 Nov 2023 |
24 Nov 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TRUQAP APPROVED IN US FOR HR+ BREAST CANCER |
17 Nov 2023 |
17 Nov 2023 |
001-11960 |
| SC 13D/A |
Open Document
|
Open Filing |
SC 13D/A |
16 Nov 2023 |
|
|
| 25-NSE |
Open Document
|
Open Filing |
|
14 Nov 2023 |
|
001-11960 |
| 6-K |
Open Document
|
Open Filing |
UPDATE ON PACIFIC-2 PHASE III TRIAL FOR IMFINZI |
14 Nov 2023 |
14 Nov 2023 |
001-11960 |
| 144 |
Open Document
|
Open Filing |
|
13 Nov 2023 |
|
001-11960 |
| SC 13D |
Open Document
|
Open Filing |
SC 13D |
09 Nov 2023 |
|
|
| 6-K |
Open Document
|
Open Filing |
DIRECTOR DECLARATION |
09 Nov 2023 |
09 Nov 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
IMFINZI COMBINATION IMPROVES PFS IN LIVER CANCER |
09 Nov 2023 |
09 Nov 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
AGREEMENT WITH ECCOGENE FOR CLINICAL STAGE GLP-1RA |
09 Nov 2023 |
09 Nov 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
9M AND Q3 2023 RESULTS |
09 Nov 2023 |
02 Nov 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Nov 2023 |
01 Nov 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA CELL & GENE THERAPY DEAL W/ CELLECTIS |
01 Nov 2023 |
01 Nov 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA SETTLES NEXIUM LIABILITY LITIGATIONS |
03 Oct 2023 |
03 Oct 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
02 Oct 2023 |
02 Oct 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DATO-DXD IMPROVED PFS IN BREAST CANCER |
25 Sep 2023 |
22 Sep 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ALEXION COMPLETES PFIZER GENE THERAPY AGREEMENT |
20 Sep 2023 |
20 Sep 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ENHERTU RECOMMENDED IN EU FOR HER2-MUTANT NSCLC |
15 Sep 2023 |
15 Sep 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FASENRA PHASE III EGPA TRIAL MET PRIMARY ENDPOINT |
11 Sep 2023 |
11 Sep 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
UPDATE ON US REVIEW OF ULTOMIRIS FOR NMOSD |
06 Sep 2023 |
06 Sep 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Sep 2023 |
01 Sep 2023 |
001-11960 |
| 25-NSE |
Open Document
|
Open Filing |
|
16 Aug 2023 |
|
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Aug 2023 |
01 Aug 2023 |
001-11960 |
| 6-K |
Open Document
| Data
|
Open Filing |
FORM 6K |
28 Jul 2023 |
30 Jun 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ALEXION ENTERS GENE THERAPY AGREEMENT WITH PFIZER |
28 Jul 2023 |
28 Jul 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
BEYFORTUS APPROVED IN US FOR INFANT RSV PREVENTION |
17 Jul 2023 |
17 Jul 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
03 Jul 2023 |
03 Jul 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DATO-DXD SIGNIFICANTLY IMPROVED PFS IN LUNG CANCER |
03 Jul 2023 |
03 Jul 2023 |
001-11960 |
| 11-K |
Open Document
|
Open Filing |
ANNUAL REPORT |
28 Jun 2023 |
31 Dec 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
NIRSEVIMAB RECOMMENDED FOR INFANT RSV PROTECTION |
09 Jun 2023 |
09 Jun 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA AGREEMENT WITH QUELL THERAPEUTICS |
09 Jun 2023 |
09 Jun 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
IMFINZI IMPROVED PCR IN GASTRIC AND GEJ CANCERS |
02 Jun 2023 |
02 Jun 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
BLOCK LISTING INTERIM REVIEW |
01 Jun 2023 |
01 Jun 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Jun 2023 |
01 Jun 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
LYNPARZA APPROVED IN US FOR BRCAM PROSTATE CANCER |
01 Jun 2023 |
01 Jun 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
IMFINZI + LYNPARZA PROLONGED PFS IN ENDOMETRIAL CANCER |
26 May 2023 |
26 May 2023 |
001-11960 |
| 25-NSE |
Open Document
|
Open Filing |
|
25 May 2023 |
|
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTORATE CHANGE |
22 May 2023 |
22 May 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TAGRISSO PLUS CHEMO IMPROVED PFS IN LUNG CANCER |
17 May 2023 |
17 May 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
09 May 2023 |
09 May 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FARXIGA EXTENDED IN THE US FOR HEART FAILURE |
09 May 2023 |
09 May 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
02 May 2023 |
02 May 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ODAC VOTE ON LYNPARZA COMBO IN PROSTATE CANCER |
02 May 2023 |
02 May 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
02 May 2023 |
02 May 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
1ST QUARTER RESULTS |
27 Apr 2023 |
27 Apr 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
RESULT OF AGM |
27 Apr 2023 |
27 Apr 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FORM 6-K |
27 Apr 2023 |
27 Apr 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
BOARD COMMITTEE CHANGES |
27 Apr 2023 |
27 Apr 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR DECLARATION |
26 Apr 2023 |
26 Apr 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
UPDATE TO ARRANGEMENTS WITH SOBI AND SANOFI |
11 Apr 2023 |
11 Apr 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
LYNPARZA + IMFINZI MET ENDPOINT IN OVARIAN CANCER |
05 Apr 2023 |
05 Apr 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
03 Apr 2023 |
03 Apr 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ULTOMIRIS RECOMMENDED FOR NMOSD EU APPROVAL |
03 Apr 2023 |
03 Apr 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA COMPLETES KYM AGREEMENT FOR CMG901 |
30 Mar 2023 |
30 Mar 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
27 Mar 2023 |
27 Mar 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FORM 6-K |
22 Mar 2023 |
22 Mar 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
NOTICE OF AGM |
22 Mar 2023 |
22 Mar 2023 |
001-11960 |
| CERT |
Open Document
|
Open Filing |
|
15 Mar 2023 |
|
001-11960 |
| 8-A12B |
Open Document
|
Open Filing |
8-A12B |
13 Mar 2023 |
|
001-11960 |
| 6-K |
Open Document
|
Open Filing |
IMFINZI IMPROVED EFS IN RESECTABLE LUNG CANCER |
09 Mar 2023 |
09 Mar 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
08 Mar 2023 |
08 Mar 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
08 Mar 2023 |
08 Mar 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ENHERTU DESTINY-PANTUMOR02 SHOWS POSITIVE RESULTS |
06 Mar 2023 |
06 Mar 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FORM 6-K |
03 Mar 2023 |
03 Mar 2023 |
001-11960 |
| 424B2 |
Open Document
|
Open Filing |
424B2 |
02 Mar 2023 |
|
333-256406 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Mar 2023 |
01 Mar 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA PRICES A $2.25BN BOND OFFERING |
01 Mar 2023 |
01 Mar 2023 |
001-11960 |
| FWP |
Open Document
|
Open Filing |
FWP |
01 Mar 2023 |
|
333-256406 |
| 424B2 |
Open Document
|
Open Filing |
424B2 |
28 Feb 2023 |
|
333-256406 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA PRICES A EUR1.5BN BOND OFFERING |
24 Feb 2023 |
24 Feb 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA ACQUIRES CINCOR FOR CARDIORENAL ASSET |
24 Feb 2023 |
24 Feb 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
24 Feb 2023 |
24 Feb 2023 |
001-11960 |
| SC TO-T/A |
Open Document
|
Open Filing |
SC TO-T/A |
24 Feb 2023 |
|
|
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA ENTERS AGREEMENT WITH KYM FOR CMG901 |
23 Feb 2023 |
23 Feb 2023 |
001-11960 |
| SC TO-T/A |
Open Document
|
Open Filing |
SC TO-T |
23 Feb 2023 |
|
|
| 6-K |
Open Document
|
Open Filing |
FILING OF FORM 20-F WITH SEC |
22 Feb 2023 |
22 Feb 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FORM 6-K |
21 Feb 2023 |
21 Feb 2023 |
001-11960 |
| IRANNOTICE |
Open Document
|
Open Filing |
IRANNOTICE |
21 Feb 2023 |
|
001-11960 |
| 20-F |
Open Document
| Data
|
Open Filing |
FORM 20-F |
21 Feb 2023 |
31 Dec 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ANNUAL FINANCIAL REPORT |
21 Feb 2023 |
21 Feb 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
13 Feb 2023 |
13 Feb 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
13 Feb 2023 |
13 Feb 2023 |
001-11960 |
| SC 13G/A |
Open Document
|
Open Filing |
SC 13G/A |
10 Feb 2023 |
|
|
| SC 13G/A |
Open Document
|
Open Filing |
SC 13G/A |
10 Feb 2023 |
|
|
| 6-K |
Open Document
|
Open Filing |
FINAL RESULTS |
09 Feb 2023 |
09 Feb 2023 |
001-11960 |
| SC TO-T/A |
Open Document
|
Open Filing |
SC TO-T/A |
03 Feb 2023 |
|
|
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Feb 2023 |
01 Feb 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
UPDATE ON EVUSHELD US EUA |
26 Jan 2023 |
26 Jan 2023 |
001-11960 |
| SC 13G/A |
Open Document
|
Open Filing |
|
24 Jan 2023 |
|
005-55247 |
| SC TO-T |
Open Document
|
Open Filing |
SC TO-T |
23 Jan 2023 |
|
|
| 6-K |
Open Document
|
Open Filing |
ACQUISITION OF NEOGENE THERAPEUTICS COMPLETED |
17 Jan 2023 |
17 Jan 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
AIRSUPRA (PT027) APPROVED IN US FOR ASTHMA |
11 Jan 2023 |
11 Jan 2023 |
001-11960 |
| SC TO-C |
Open Document
|
Open Filing |
SC TO-C |
09 Jan 2023 |
|
|
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA ACQUIRE CINCOR FOR CARDIORENAL ASSET |
09 Jan 2023 |
09 Jan 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
03 Jan 2023 |
03 Jan 2023 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
30 Dec 2022 |
30 Dec 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
CALQUENCE JAPAN APPROVAL FOR TREATMENT-NAIVE CLL |
28 Dec 2022 |
28 Dec 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
IMFINZI, IMJUDO APPROVED IN JAPAN FOR 3 CANCERS |
28 Dec 2022 |
28 Dec 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
IMFINZI APPROVED IN EU FOR BILIARY TRACT CANCER |
21 Dec 2022 |
21 Dec 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
LYNPARZA APPROVED IN EU FOR PROSTATE CANCER |
21 Dec 2022 |
21 Dec 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ENHERTU RECOMMENDED FOR APPROVAL IN THE EU BY CHMP FOR PATIENTS WITH HER2-LOW ME |
19 Dec 2022 |
19 Dec 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ENHERTU APPROVED IN THE EU FOR PATIENTS WITH PREVIOUSLY TREATED HER2-POSITIVE AD |
19 Dec 2022 |
19 Dec 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
IMFINZI PLUS IMJUDO RECOMMENDED FOR APPROVAL IN THE EU BY CHMP FOR THE TREATMENT |
19 Dec 2022 |
19 Dec 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
UPDATE ON PEARL PHASE III TRIAL OF IMFINZI MONOTHERAPY IN STAGE IV NON-SMALL CEL |
19 Dec 2022 |
19 Dec 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FORXIGA CHMP OPINION FOR SYMPTOMATIC CHRONIC HF |
19 Dec 2022 |
19 Dec 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
UPDATE ON US REVIEW OF LYNPARZA PROPEL SNDA |
15 Dec 2022 |
15 Dec 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
CAPIVASERTIB PFS IN HR-POSITIVE BREAST CANCER |
08 Dec 2022 |
08 Dec 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Dec 2022 |
01 Dec 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
BLOCK LISTING INTERIM REVIEW |
01 Dec 2022 |
01 Dec 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA ANNOUNCES SALE OF WEST CHESTER SITE |
30 Nov 2022 |
30 Nov 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA TO ACQUIRE NEOGENE THERAPEUTICS |
29 Nov 2022 |
29 Nov 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
23 Nov 2022 |
23 Nov 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ENHERTU RECOMMENDED FOR EU APPROVAL IN GASTRIC |
14 Nov 2022 |
14 Nov 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
IMFINZI RECOMMENDED FOR APPROVAL IN THE EU FOR BTC |
14 Nov 2022 |
14 Nov 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
LYNPARZA COMBO RECOMMENDED IN THE EU FOR MCRPC |
14 Nov 2022 |
14 Nov 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
IMFINZI + IMJUDO APPROVED IN US FOR LUNG CANCER |
14 Nov 2022 |
11 Nov 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
YTD AND Q3 2022 RESULTS |
10 Nov 2022 |
10 Nov 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FDA ADVISORY COMMITTEE RECOMMENDS PT027 IN ASTHMA |
09 Nov 2022 |
09 Nov 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
BEYFORTUS (NIRSEVIMAB) APPROVED IN EU |
04 Nov 2022 |
04 Nov 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Nov 2022 |
01 Nov 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
CAPIVASERTIB PHASE III TRIAL MET PRIMARY ENDPOINTS |
26 Oct 2022 |
26 Oct 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
UPDATE ON MESSINA PHASE III TRIAL |
25 Oct 2022 |
25 Oct 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
IMFINZI + IMJUDO APPROVED IN ADVANCED LIVER CANCER |
24 Oct 2022 |
24 Oct 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
03 Oct 2022 |
03 Oct 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
BOARD COMMITTEE CHANGES |
30 Sep 2022 |
30 Sep 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
KOSELUGO APPROVED IN JAPAN FOR NF1 |
27 Sep 2022 |
27 Sep 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TEZSPIRE APPROVED IN JAPAN FOR SEVERE ASTHMA |
27 Sep 2022 |
27 Sep 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ULTOMIRIS APPROVED IN EU FOR GMG |
23 Sep 2022 |
23 Sep 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
LYNPARZA APPROVED IN CHINA FOR OVARIAN CANCER |
22 Sep 2022 |
22 Sep 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TEZSPIRE APPROVED IN THE EU FOR SEVERE ASTHMA |
21 Sep 2022 |
21 Sep 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
EVUSHELD APPROVED IN EU FOR COVID-19 TREATMENT |
20 Sep 2022 |
20 Sep 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DANICOPAN PHASE III TRIAL MET PRIMARY ENDPOINT |
16 Sep 2022 |
16 Sep 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
NIRSEVIMAB RECOMMENDED FOR APPROVAL IN EU BY CHMP |
16 Sep 2022 |
16 Sep 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
EVUSHELD POSITIVE CHMP OPINION IN EU |
16 Sep 2022 |
16 Sep 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FORXIGA APPROVED IN CHINA FOR CKD |
06 Sep 2022 |
06 Sep 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
IMFINZI APPROVED IN US FOR BILIARY TRACT CANCER |
06 Sep 2022 |
06 Sep 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Sep 2022 |
01 Sep 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
EVUSHELD APPROVED FOR COVID-19 IN JAPAN |
30 Aug 2022 |
30 Aug 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FARXIGA REDUCED RISK OF CV DEATH OR WORSENING HF |
30 Aug 2022 |
30 Aug 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FARXIGA SHOWS CV MORTALITY BENEFIT ACROSS EF RANGE |
30 Aug 2022 |
30 Aug 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ULTOMIRIS APPROVED IN JAPAN FOR GMG |
25 Aug 2022 |
25 Aug 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TAGRISSO APPROVED IN JAPAN FOR EARLY LUNG CANCER |
25 Aug 2022 |
25 Aug 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
LYNPARZA APPROVED IN JAPAN FOR EARLY BREAST CANCER |
25 Aug 2022 |
25 Aug 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
LYNPARZA GRANTED FDA PRIORITY REVIEW FOR PROPEL |
16 Aug 2022 |
16 Aug 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ENHERTU IMPROVED PFS IN MBC IN DESTINY-BREAST02 |
15 Aug 2022 |
15 Aug 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ENHERTU APPROVED IN US FOR HER2-MUTANT NSCLC |
12 Aug 2022 |
12 Aug 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ACQUISITION OF TENEOTWO COMPLETED |
11 Aug 2022 |
11 Aug 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ENHERTU APPROVED IN THE US FOR HER2-LOW MBC |
08 Aug 2022 |
08 Aug 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
LYNPARZA APPROVED IN EU FOR EARLY BREAST CANCER |
04 Aug 2022 |
04 Aug 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
01 Aug 2022 |
01 Aug 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Aug 2022 |
01 Aug 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
01 Aug 2022 |
01 Aug 2022 |
001-11960 |
| 6-K |
Open Document
| Data
|
Open Filing |
FORM 6-K |
29 Jul 2022 |
30 Jun 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
CHAIR SUCCESSION |
29 Jul 2022 |
29 Jul 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TEZSPIRE RECOMMENDED FOR EU APPROVAL IN ASTHMA |
25 Jul 2022 |
25 Jul 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ULTOMIRIS RECOMMENDED FOR EU APPROVAL FOR GMG |
25 Jul 2022 |
25 Jul 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ENHERTU GRANTED PRIORITY REVIEW FOR HER2-LOW MBC |
25 Jul 2022 |
25 Jul 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ENHERTU APPROVED IN EU FOR HER2-POSITIVE MBC |
19 Jul 2022 |
19 Jul 2022 |
001-11960 |
| SC 13G |
Open Document
|
Open Filing |
|
08 Jul 2022 |
|
005-55247 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA TO ACQUIRE TENEOTWO AND T CELL ENGAGER |
05 Jul 2022 |
05 Jul 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Jul 2022 |
01 Jul 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
IMFINZI IMPROVED PCR IN RESECTABLE LUNG CANCER |
30 Jun 2022 |
30 Jun 2022 |
001-11960 |
| 11-K |
Open Document
|
Open Filing |
ANNUAL REPORT |
29 Jun 2022 |
31 Dec 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ENHERTU RECOMMENDED FOR BREAST CANCER EU APPROVAL |
27 Jun 2022 |
27 Jun 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
LYNPARZA RECOMMENDED IN EU FOR EARLY BREAST CANCER |
27 Jun 2022 |
27 Jun 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
EPLONTERSEN PH III TRIAL MET CO-PRIMARY ENDPOINTS |
21 Jun 2022 |
21 Jun 2022 |
001-11960 |
| 25-NSE |
Open Document
|
Open Filing |
|
10 Jun 2022 |
|
001-11960 |
| 25-NSE |
Open Document
|
Open Filing |
|
09 Jun 2022 |
|
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ENHERTU EFFICACY RESULTS IN HER2-LOW BREAST CANCER |
06 Jun 2022 |
06 Jun 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
BLOCK LISTING INTERIM REVIEW |
01 Jun 2022 |
01 Jun 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Jun 2022 |
01 Jun 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
20 May 2022 |
20 May 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
APPOINTMENT OF JOINT CORPORATE BROKERS |
09 May 2022 |
09 May 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
06 May 2022 |
06 May 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ENHERTU APPROVED IN US FOR 2L HER2+ BREAST CANCER |
05 May 2022 |
05 May 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FARXIGA HFPEF PHASE III TRIAL MET PRIMARY ENDPOINT |
05 May 2022 |
05 May 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ULTOMIRIS NMOSD PH. III TRIAL MET PRIMARY ENDPOINT |
05 May 2022 |
05 May 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
IMFINZI COMBO GRANTED PRIORITY REVIEW FOR BTC |
04 May 2022 |
04 May 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
03 May 2022 |
03 May 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
RESULT OF AGM |
29 Apr 2022 |
29 Apr 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA PLANS NEW R&D CENTRE IN MASSACHUSETTS |
29 Apr 2022 |
29 Apr 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FIRST QUARTER 2022 RESULTS |
29 Apr 2022 |
29 Apr 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ULTOMIRIS APPROVED IN THE US FOR ADULTS WITH GMG |
28 Apr 2022 |
28 Apr 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ENHERTU GRANTED BTD FOR HER2-LOW BREAST CANCER |
27 Apr 2022 |
27 Apr 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TREMELIMUMAB US PRIORITY REVIEW FOR IMFINZI COMBO |
25 Apr 2022 |
25 Apr 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ENHERTU GRANTED PRIORITY REVIEW FOR HER2M NSCLC |
19 Apr 2022 |
19 Apr 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Apr 2022 |
01 Apr 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ONDEXXYA APPROVED IN JAPAN FOR FXAI REVERSAL |
29 Mar 2022 |
29 Mar 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
EVUSHELD APPROVED IN THE EU FOR COVID-19 |
28 Mar 2022 |
28 Mar 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
25 Mar 2022 |
25 Mar 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
EVUSHELD POSITIVE EU CHMP OPINION |
24 Mar 2022 |
24 Mar 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
UPDATE ON CALLA PHASE III TRIAL OF CONCURRENT USE OF IMFINZI AND CHEMORADIOTHERA |
24 Mar 2022 |
24 Mar 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
NOTICE OF AGM |
23 Mar 2022 |
23 Mar 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FORM 6-K |
23 Mar 2022 |
23 Mar 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
SETTLEMENT OF PATENT LITIGATION FOR ULTOMIRIS |
17 Mar 2022 |
17 Mar 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
LYNPARZA APPROVED IN US FOR EARLY BREAST CANCER |
14 Mar 2022 |
14 Mar 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
UPDATE ON US REVIEW OF FASENRA IN NASAL POLYPS |
14 Mar 2022 |
14 Mar 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
09 Mar 2022 |
09 Mar 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
07 Mar 2022 |
07 Mar 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
01 Mar 2022 |
01 Mar 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Mar 2022 |
01 Mar 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA AND NEURIMMUNE CLOSE DEAL FOR NI006 |
01 Mar 2022 |
01 Mar 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FILING OF FORM 20-F WITH SEC |
23 Feb 2022 |
23 Feb 2022 |
001-11960 |
| IRANNOTICE |
Open Document
|
Open Filing |
IRANNOTICE |
22 Feb 2022 |
|
001-11960 |
| 20-F |
Open Document
| Data
|
Open Filing |
FORM 20F |
22 Feb 2022 |
31 Dec 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
CHAIR SUCCESSION PLANNING UPDATE AND ANNUAL REPORT |
22 Feb 2022 |
22 Feb 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ENHERTU IMPROVES PFS AND OS IN HER2-LOW BC |
22 Feb 2022 |
22 Feb 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
SAPHNELO APPROVED IN EU FOR SLE |
16 Feb 2022 |
16 Feb 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
LYNPARZA COMBO DELAYS PROGRESSION RISK IN PROSTATE |
15 Feb 2022 |
15 Feb 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
11 Feb 2022 |
11 Feb 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
AZN: FULL YEAR AND Q4 2021 RESULTS |
10 Feb 2022 |
10 Feb 2022 |
001-11960 |
| SC 13G/A |
Open Document
|
Open Filing |
|
07 Feb 2022 |
|
005-55247 |
| SC 13G/A |
Open Document
|
Open Filing |
SEC SCHEDULE 13G |
04 Feb 2022 |
|
005-55247 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Feb 2022 |
01 Feb 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
IMFINZI IMPROVES SURVIVAL IN BILIARY TRACT CANCER |
19 Jan 2022 |
19 Jan 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
IMFINZI COMBO SHOWS UNPRECEDENTED SURVIVAL IN HCC |
19 Jan 2022 |
19 Jan 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ENHERTU GRANTED PRIORITY REVIEW FOR BREAST CANCER |
18 Jan 2022 |
18 Jan 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA AND NEURIMMUNE SIGN DEAL FOR NI006 |
07 Jan 2022 |
07 Jan 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TRANSFER OF RIGHTS TO EKLIRA, DUAKLIR COMPLETED |
05 Jan 2022 |
05 Jan 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
04 Jan 2022 |
04 Jan 2022 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA AND IONIS CLOSE EPLONTERSEN DEAL |
29 Dec 2021 |
29 Dec 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ULTOMIRIS ACCEPTED FOR FDA PRIORITY REVIEW FOR GMG |
21 Dec 2021 |
21 Dec 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TEZSPIRE APPROVED IN THE US FOR SEVERE ASTHMA |
20 Dec 2021 |
20 Dec 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
SAPHNELO RECOMMENDED FOR EU APPROVAL FOR SLE |
20 Dec 2021 |
20 Dec 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
15 Dec 2021 |
15 Dec 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
EVUSHELD US FDA EUA |
09 Dec 2021 |
09 Dec 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA, IONIS TO COLLABORATE ON EPLONTERSEN |
07 Dec 2021 |
07 Dec 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
BLOCK LISTING INTERIM REVIEW |
01 Dec 2021 |
01 Dec 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Dec 2021 |
01 Dec 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
LYNPARZA GRANTED FDA PRIORITY REVIEW FOR OLYMPIA |
30 Nov 2021 |
30 Nov 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
15 Nov 2021 |
15 Nov 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
AZN: YEAR TO DATE AND Q3 2021 RESULTS |
12 Nov 2021 |
12 Nov 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Nov 2021 |
01 Nov 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA TO TRANSFER RIGHTS TO EKLIRA, DUAKLIR |
01 Nov 2021 |
01 Nov 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
IMFINZI IMPROVED SURVIVAL IN BILIARY TRACT CANCER |
25 Oct 2021 |
25 Oct 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
AZ RECOMMENDS ADS HOLDERS REJECT MINI-TENDER OFFER |
18 Oct 2021 |
18 Oct 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
IMFINZI & TREMELIMUMAB IMPROVED OS IN LIVER CANCER |
15 Oct 2021 |
15 Oct 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
AZD7442 PHIII TRIAL POSITIVE IN COVID OUTPATIENTS |
12 Oct 2021 |
12 Oct 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ENHERTU GRANTED BTD FOR BREAST CANCER |
04 Oct 2021 |
04 Oct 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Oct 2021 |
01 Oct 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
30 Sep 2021 |
30 Sep 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA TO FULLY ACQUIRE CAELUM BIOSCIENCES |
29 Sep 2021 |
29 Sep 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
SAPHNELO APPROVED IN JAPAN FOR SLE |
28 Sep 2021 |
28 Sep 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
LYNPARZA PROPEL TRIAL MEETS PRIMARY ENDPOINT |
24 Sep 2021 |
24 Sep 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
BOARD COMMITTEE CHANGE |
23 Sep 2021 |
23 Sep 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
NEW SUSTAINABILITY COMMITTEE OF THE BOARD |
23 Sep 2021 |
23 Sep 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA $360M IRISH MANUFACTURING INVESTMENT |
21 Sep 2021 |
21 Sep 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ENHERTU REDUCED RISK OF DISEASE PROGRESSION BY 72% |
20 Sep 2021 |
20 Sep 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
IMFINZI IMPROVES SURVIVAL IN NSCLC IN POSEIDON |
09 Sep 2021 |
09 Sep 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FIXED-DOSE COMBINATION OF ALBUTEROL AND BUDESONIDE (PT027) DEMONSTRATED SIGNIFIC |
09 Sep 2021 |
09 Sep 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ULTOMIRIS APPROVED IN EU FOR CHILDREN WITH PNH |
03 Sep 2021 |
03 Sep 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Sep 2021 |
01 Sep 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FORXIGA APPROVED IN JAPAN FOR CKD |
26 Aug 2021 |
26 Aug 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ALXN1840 WILSON PHASE III MET PRIMARY ENDPOINT |
26 Aug 2021 |
26 Aug 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
UPDATE ON ULTOMIRIS PHASE III ALS TRIAL |
20 Aug 2021 |
20 Aug 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
AZD7442 PROPHYLAXIS TRIAL MET PRIMARY ENDPOINT |
20 Aug 2021 |
20 Aug 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
16 Aug 2021 |
16 Aug 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
UPDATE ON US REVIEW OF ROXADUSTAT |
11 Aug 2021 |
11 Aug 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FORXIGA APPROVED IN THE EU FOR CKD |
09 Aug 2021 |
09 Aug 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ENHERTU HEAD-TO-HEAD TRIAL MEETS PRIMARY ENDPOINT |
09 Aug 2021 |
09 Aug 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
02 Aug 2021 |
02 Aug 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
SAPHNELO APPROVED IN THE US FOR SLE |
02 Aug 2021 |
02 Aug 2021 |
001-11960 |
| 6-K/A |
Open Document
| Data
|
Open Filing |
FORM 6-K/A |
30 Jul 2021 |
30 Jun 2021 |
001-11960 |
| 6-K |
Open Document
| Data
|
Open Filing |
FORM 6-K |
30 Jul 2021 |
30 Jun 2021 |
001-11960 |
| SC 13G |
Open Document
|
Open Filing |
SC 13G |
27 Jul 2021 |
|
|
| 6-K |
Open Document
|
Open Filing |
ULTOMIRIS RECOMMENDED IN EU FOR CHILDREN WITH PNH |
26 Jul 2021 |
26 Jul 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTORATE CHANGE |
22 Jul 2021 |
22 Jul 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FORM 6-K |
21 Jul 2021 |
21 Jul 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
21 Jul 2021 |
21 Jul 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
21 Jul 2021 |
21 Jul 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ACQUISITION OF ALEXION COMPLETED |
21 Jul 2021 |
21 Jul 2021 |
001-11960 |
| F-6EF |
Open Document
|
Open Filing |
REGISTRATION OF AMERICAN DEPOSITAR RECEIPT SHARES |
19 Jul 2021 |
|
333-258002 |
| 6-K |
Open Document
|
Open Filing |
IMFINZI APPROVED IN CHINA FOR EXTENSIVE-STAGE SCLC |
19 Jul 2021 |
19 Jul 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
STATUS ON US FDA ADVISORY COMMITTEE FOR ROXADUSTAT |
16 Jul 2021 |
16 Jul 2021 |
001-11960 |
| 425 |
Open Document
|
Open Filing |
425 |
14 Jul 2021 |
|
|
| 425 |
Open Document
|
Open Filing |
425 |
14 Jul 2021 |
|
|
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA-ALEXION TRANSACTION CLEARED IN THE UK |
14 Jul 2021 |
14 Jul 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TEZEPELUMAB GRANTED FDA PRIORITY REVIEW FOR ASTHMA |
08 Jul 2021 |
08 Jul 2021 |
001-11960 |
| 425 |
Open Document
|
Open Filing |
425 |
06 Jul 2021 |
|
|
| 425 |
Open Document
|
Open Filing |
425 |
06 Jul 2021 |
|
|
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA-ALEXION TRANSACTION CLEARED IN THE EU |
06 Jul 2021 |
06 Jul 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Jul 2021 |
01 Jul 2021 |
001-11960 |
| 425 |
Open Document
|
Open Filing |
425 |
30 Jun 2021 |
|
|
| 11-K |
Open Document
|
Open Filing |
FORM 11-K |
29 Jun 2021 |
31 Dec 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FORXIGA RECOMMENDED IN EU FOR PATIENTS WITH CKD |
28 Jun 2021 |
28 Jun 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
NIRSEVIMAB PHII/III TRIAL CONFIRMS SAFETY PROFILE |
28 Jun 2021 |
28 Jun 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
LYNPARZA APPROVED IN CHINA FOR PROSTATE CANCER |
24 Jun 2021 |
24 Jun 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ORPATHYS APPROVED IN CHINA FOR LUNG CANCER |
23 Jun 2021 |
23 Jun 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
KOSELUGO APPROVED IN THE EU FOR CHILDREN WITH NF1 |
22 Jun 2021 |
22 Jun 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
UPDATE ON AZD7442 STORM CHASER TRIAL |
15 Jun 2021 |
15 Jun 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
CALQUENCE HEAD-TO-HEAD RESULTS VERSUS IBRUTINIB |
07 Jun 2021 |
07 Jun 2021 |
001-11960 |
| 425 |
Open Document
|
Open Filing |
425 |
04 Jun 2021 |
|
|
| 425 |
Open Document
|
Open Filing |
425 |
04 Jun 2021 |
|
|
| 6-K |
Open Document
|
Open Filing |
LYNPARZA REDUCED RECURRENCE RISK IN BREAST CANCER |
04 Jun 2021 |
04 Jun 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA APPOINTS NEW CHIEF FINANCIAL OFFICER |
04 Jun 2021 |
04 Jun 2021 |
001-11960 |
| CERT |
Open Document
|
Open Filing |
|
03 Jun 2021 |
|
001-11960 |
| 6-K |
Open Document
|
Open Filing |
PUBLICATION OF FINAL TERMS |
02 Jun 2021 |
02 Jun 2021 |
001-11960 |
| 8-A12B |
Open Document
|
Open Filing |
8-A12B |
01 Jun 2021 |
|
001-11960 |
| 6-K |
Open Document
|
Open Filing |
BLOCK LISTING INTERIM REVIEW |
01 Jun 2021 |
01 Jun 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Jun 2021 |
01 Jun 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FORM 6-K |
28 May 2021 |
28 May 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TAGRISSOAPPROVED IN THE EU FOR THE ADJUVANT TREATMENT OFPATIENTS WITH EARLY-STAG |
28 May 2021 |
28 May 2021 |
001-11960 |
| 424B2 |
Open Document
|
Open Filing |
424B2 |
27 May 2021 |
|
333-256406 |
| 425 |
Open Document
|
Open Filing |
425 |
27 May 2021 |
|
|
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA PRICES A EUR800M BOND OFFERING |
27 May 2021 |
27 May 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA PRICES A $7BN BOND OFFERING |
26 May 2021 |
26 May 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FORM 6-K |
26 May 2021 |
26 May 2021 |
001-11960 |
| FWP |
Open Document
|
Open Filing |
FWP |
26 May 2021 |
|
333-256406 |
| FWP |
Open Document
|
Open Filing |
FWP |
26 May 2021 |
|
333-256406 |
| 6-K |
Open Document
|
Open Filing |
EMTN PROGRAMME UPDATE - PUBLICATION OF PROSPECTUS |
25 May 2021 |
25 May 2021 |
001-11960 |
| 425 |
Open Document
|
Open Filing |
425 |
24 May 2021 |
|
|
| 424B2 |
Open Document
|
Open Filing |
424B2 |
24 May 2021 |
|
333-256406 |
| F-3ASR |
Open Document
|
Open Filing |
F-3ASR |
24 May 2021 |
|
333-256406 |
| 6-K |
Open Document
|
Open Filing |
FORM 6-K |
24 May 2021 |
24 May 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA COVID-19 VACCINE VAXZEVRIA AUTHORISED FOR EMERGENCY USE IN JAPAN |
21 May 2021 |
21 May 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
18 May 2021 |
18 May 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
RESULT OF AGM |
11 May 2021 |
11 May 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
SHAREHOLDERS VOTE IN FAVOUR OF ALEXION ACQUISITION |
11 May 2021 |
11 May 2021 |
001-11960 |
| 425 |
Open Document
|
Open Filing |
425 |
07 May 2021 |
|
|
| 6-K |
Open Document
|
Open Filing |
IMFINZI + TREMELIMUMAB SHOWED SURVIVAL IN POSEIDON |
07 May 2021 |
07 May 2021 |
001-11960 |
| 425 |
Open Document
|
Open Filing |
425 |
06 May 2021 |
|
|
| 425 |
Open Document
|
Open Filing |
425 |
05 May 2021 |
|
|
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
04 May 2021 |
04 May 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FARXIGA APPROVED IN THE US FOR CKD |
04 May 2021 |
04 May 2021 |
001-11960 |
| 425 |
Open Document
|
Open Filing |
425 |
30 Apr 2021 |
|
|
| 425 |
Open Document
|
Open Filing |
425 |
30 Apr 2021 |
|
|
| 425 |
Open Document
|
Open Filing |
425 |
30 Apr 2021 |
|
|
| 6-K |
Open Document
|
Open Filing |
AZN: FIRST QUARTER 2021 RESULTS |
30 Apr 2021 |
30 Apr 2021 |
001-11960 |
| 425 |
Open Document
|
Open Filing |
425 |
29 Apr 2021 |
|
|
| 6-K |
Open Document
|
Open Filing |
NIRSEVIMAB PHASE III TRIAL MET PRIMARY ENDPOINT |
26 Apr 2021 |
26 Apr 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TAGRISSO ADJUVANT RECEIVES POSITIVE CHMP OPINION |
26 Apr 2021 |
26 Apr 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
SELUMETINIB RECOMMENDED FOR EU APPROVAL IN NF1 |
26 Apr 2021 |
26 Apr 2021 |
001-11960 |
| 425 |
Open Document
|
Open Filing |
425 |
16 Apr 2021 |
|
|
| 425 |
Open Document
|
Open Filing |
425 |
16 Apr 2021 |
|
|
| 6-K |
Open Document
|
Open Filing |
US CLEARANCE OF PROPOSED ACQUISITION OF ALEXION |
16 Apr 2021 |
16 Apr 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TAGRISSO APPROVED IN CHINA IN EARLY LUNG CANCER |
14 Apr 2021 |
14 Apr 2021 |
001-11960 |
| 424B3 |
Open Document
|
Open Filing |
424B3 |
13 Apr 2021 |
|
333-253315 |
| EFFECT |
Open Document
|
Open Filing |
|
12 Apr 2021 |
|
333-253315 |
| 425 |
Open Document
|
Open Filing |
425 |
12 Apr 2021 |
|
|
| 6-K |
Open Document
|
Open Filing |
FORM 6-K |
12 Apr 2021 |
12 Apr 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
CIRCULAR AND NOTICE OF GENERAL MEETING |
12 Apr 2021 |
12 Apr 2021 |
001-11960 |
| 425 |
Open Document
|
Open Filing |
425 |
12 Apr 2021 |
|
|
| 6-K |
Open Document
|
Open Filing |
UPDATE ON FARXIGA COVID-19 DARE-19 PHASE III TRIAL |
12 Apr 2021 |
12 Apr 2021 |
001-11960 |
| F-4/A |
Open Document
|
Open Filing |
F-4/A |
09 Apr 2021 |
|
333-253315 |
| CORRESP |
Open Document
|
Open Filing |
|
08 Apr 2021 |
|
|
| SC 13G |
Open Document
|
Open Filing |
SC 13G |
08 Apr 2021 |
|
|
| 425 |
Open Document
|
Open Filing |
425 |
01 Apr 2021 |
|
|
| 425 |
Open Document
|
Open Filing |
425 |
01 Apr 2021 |
|
|
| 425 |
Open Document
|
Open Filing |
425 |
01 Apr 2021 |
|
|
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Apr 2021 |
01 Apr 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
NOTICE OF AGM |
30 Mar 2021 |
30 Mar 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FORM 6-K |
30 Mar 2021 |
30 Mar 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
25 Mar 2021 |
25 Mar 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
AZD1222 US PH3 PRIMARY ANALYSIS CONFIRMS EFFICACY |
25 Mar 2021 |
25 Mar 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA US VACCINE TRIAL MET PRIMARY ENDPOINT |
22 Mar 2021 |
22 Mar 2021 |
001-11960 |
| 4 |
Open Document
|
Open Filing |
4 |
16 Mar 2021 |
15 Mar 2021 |
001-39067 |
| 6-K |
Open Document
|
Open Filing |
DIVESTMENT OF VIELA SHAREHOLDING COMPLETED |
16 Mar 2021 |
16 Mar 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
US SUPPLY AGREEMENT FOR ADDITIONAL AZD7442 DOSES |
16 Mar 2021 |
16 Mar 2021 |
001-11960 |
| 425 |
Open Document
|
Open Filing |
425 |
12 Mar 2021 |
|
|
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
09 Mar 2021 |
09 Mar 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DESIGNATION OF EU HOME MEMBER STATE FOR EU SECURITIES REGULATION PURPOSES |
04 Mar 2021 |
04 Mar 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
US COURT DECISION FAVOURS SYMBICORT PATENTS |
03 Mar 2021 |
03 Mar 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FURTHER UPDATE ON US REGULATORY REVIEW OF ROXADUSTAT IN ANAEMIA OF CHRONIC KIDNE |
02 Mar 2021 |
02 Mar 2021 |
001-11960 |
| UPLOAD |
Open Document
|
Open Filing |
|
01 Mar 2021 |
|
|
| 6-K |
Open Document
|
Open Filing |
TRANSPARENCY DIRECTIVE VOTING RIGHTS AND CAPITAL |
01 Mar 2021 |
01 Mar 2021 |
001-11960 |
| 425 |
Open Document
|
Open Filing |
425 |
26 Feb 2021 |
|
|
| 425 |
Open Document
|
Open Filing |
425 |
25 Feb 2021 |
|
|
| 6-K |
Open Document
|
Open Filing |
VOLUNTARY WITHDRAWAL OF IMFINZI INDICATION IN ADVANCED BLADDER CANCER IN THE US |
22 Feb 2021 |
22 Feb 2021 |
001-11960 |
| F-4 |
Open Document
|
Open Filing |
F-4 |
19 Feb 2021 |
|
333-253315 |
| 6-K |
Open Document
|
Open Filing |
LYNPARZA: IDMC RECOMMEND EARLY ANALYSIS OF OLYMPIA |
17 Feb 2021 |
17 Feb 2021 |
001-11960 |
| IRANNOTICE |
Open Document
|
Open Filing |
IRANNOTICE |
16 Feb 2021 |
|
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FILING OF FORM 20-F WITH SEC |
16 Feb 2021 |
16 Feb 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
16 Feb 2021 |
16 Feb 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ANNUAL FINANCIAL REPORT |
16 Feb 2021 |
16 Feb 2021 |
001-11960 |
| 20-F |
Open Document
| Data
|
Open Filing |
20-F |
16 Feb 2021 |
31 Dec 2020 |
001-11960 |
| 425 |
Open Document
|
Open Filing |
425 |
12 Feb 2021 |
|
|
| 425 |
Open Document
|
Open Filing |
425 |
11 Feb 2021 |
|
|
| 425 |
Open Document
|
Open Filing |
425 |
11 Feb 2021 |
|
|
| 425 |
Open Document
|
Open Filing |
425 |
11 Feb 2021 |
|
|
| 425 |
Open Document
|
Open Filing |
425 |
11 Feb 2021 |
|
|
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA NON-EXECUTIVE BOARD CHANGES |
11 Feb 2021 |
11 Feb 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
AZN: FULL-YEAR 2020 RESULTS |
11 Feb 2021 |
11 Feb 2021 |
001-11960 |
| SC 13G |
Open Document
|
Open Filing |
SC 13G |
10 Feb 2021 |
|
|
| SC 13G/A |
Open Document
|
Open Filing |
SC 13G/A |
10 Feb 2021 |
|
|
| 6-K |
Open Document
|
Open Filing |
DIVESTMENT OF CRESTOR IN EUROPE COMPLETED |
10 Feb 2021 |
10 Feb 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
UPDATE ON KESTREL PHASE III TRIAL FOR IMFINZI |
05 Feb 2021 |
05 Feb 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FORXIGA APPROVED IN CHINA FOR HEART FAILURE |
04 Feb 2021 |
04 Feb 2021 |
001-11960 |
| SC 13G/A |
Open Document
|
Open Filing |
SEC SCHEDULE 13G |
03 Feb 2021 |
|
005-55247 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Feb 2021 |
01 Feb 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA AGREES TO DIVEST VIELA SHAREHOLDING |
01 Feb 2021 |
01 Feb 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
COVID-19 VACCINE AUTHORISED FOR USE BY THE EU |
01 Feb 2021 |
01 Feb 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
COVID-19 VACCINE RECEIVES POSITIVE OPINION IN EU |
29 Jan 2021 |
29 Jan 2021 |
001-11960 |
| SC 13G/A |
Open Document
|
Open Filing |
|
29 Jan 2021 |
|
005-55247 |
| 6-K |
Open Document
|
Open Filing |
BLOCK LISTING APPLICATION |
26 Jan 2021 |
26 Jan 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
SYMBICORT APPROVED IN CHINA FOR MILD ASTHMA |
26 Jan 2021 |
26 Jan 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
CALQUENCE APPROVED IN JAPAN FOR CLL |
25 Jan 2021 |
25 Jan 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
CALQUENCE MET PRIMARY EFFICACY ENDPOINT IN HEAD-TO-HEAD TRIAL AGAINST IBRUTINIB |
25 Jan 2021 |
25 Jan 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ENHERTU APPROVED IN THE EU FOR BREAST CANCER |
20 Jan 2021 |
20 Jan 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ENHERTU APPROVED IN THE US FOR GASTRIC CANCER |
19 Jan 2021 |
19 Jan 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
IMFINZI APPROVED IN THE EU FOR LESS-FREQUENT, FIXED- DOSE USE IN UNRESECTABLE NO |
15 Jan 2021 |
15 Jan 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FARXIGA GRANTED PRIORITY REVIEW IN THE US FOR THE TREATMENT OF PATIENTS WITH CHR |
06 Jan 2021 |
06 Jan 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
04 Jan 2021 |
04 Jan 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ATACAND DIVESTMENT TO CHEPLAPHARM IN MORE THAN 70 COUNTRIES COMPLETED |
04 Jan 2021 |
04 Jan 2021 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA'S COVID-19 VACCINE AUTHORISED IN UK |
30 Dec 2020 |
30 Dec 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
LYNPARZA APPROVED IN JAPAN FOR THE TREATMENT OF ADVANCED OVARIAN, PROSTATE AND P |
29 Dec 2020 |
29 Dec 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TAGRISSO APPROVED IN THE US FOR THE ADJUVANT TREATMENT OF PATIENTS WITH EARLY-ST |
21 Dec 2020 |
21 Dec 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
UPDATE ON US REGULATORY REVIEW OF ROXADUSTAT IN ANAEMIA OF CHRONIC KIDNEY DISEAS |
21 Dec 2020 |
21 Dec 2020 |
001-11960 |
| 425 |
Open Document
|
Open Filing |
425 |
18 Dec 2020 |
|
|
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
17 Dec 2020 |
17 Dec 2020 |
001-11960 |
| 425 |
Open Document
|
Open Filing |
425 |
17 Dec 2020 |
|
|
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
16 Dec 2020 |
16 Dec 2020 |
001-11960 |
| 425 |
Open Document
|
Open Filing |
425 |
15 Dec 2020 |
|
|
| 6-K |
Open Document
|
Open Filing |
IMFINZI NEW DOSE RECEIVES POSITIVE EU CHMP OPINION |
15 Dec 2020 |
15 Dec 2020 |
001-11960 |
| 425 |
Open Document
|
Open Filing |
425 |
14 Dec 2020 |
|
|
| 425 |
Open Document
|
Open Filing |
425 |
14 Dec 2020 |
|
|
| 425 |
Open Document
|
Open Filing |
425 |
14 Dec 2020 |
|
|
| 425 |
Open Document
|
Open Filing |
425 |
14 Dec 2020 |
|
|
| 6-K |
Open Document
|
Open Filing |
TRASTUZUMAB DERUXTECAN POSITIVE CHMP |
14 Dec 2020 |
14 Dec 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TRIXEO AEROSPHERE APPROVED IN THE EU FOR COPD |
14 Dec 2020 |
14 Dec 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA TO ACQUIRE ALEXION PHARMACEUTICALS INC |
14 Dec 2020 |
14 Dec 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
BLOCK LISTING INTERIM REVIEW |
01 Dec 2020 |
01 Dec 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Dec 2020 |
01 Dec 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
CRESTOR TO BE DIVESTED TO GRUNENTHAL IN EUROPE |
01 Dec 2020 |
01 Dec 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FORXIGA APPROVED IN JAPAN FOR CHRONIC HEART FAILURE |
30 Nov 2020 |
30 Nov 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
AZD1222 VACCINE EFFECTIVE AGAINST COVID-19 |
23 Nov 2020 |
23 Nov 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
IMFINZI NEW DOSING APPROVED IN THE US |
20 Nov 2020 |
20 Nov 2020 |
001-11960 |
| 25-NSE |
Open Document
|
Open Filing |
|
13 Nov 2020 |
|
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TEZEPELUMAB PHASE III TRIAL MET PRIMARY ENDPOINT |
10 Nov 2020 |
10 Nov 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
CALQUENCE APPROVED IN THE EU FOR CLL |
09 Nov 2020 |
09 Nov 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
BRILINTA APPROVED IN THE US IN STROKE |
06 Nov 2020 |
06 Nov 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
AZN: YEAR-TO-DATE AND Q3 2020 RESULTS |
05 Nov 2020 |
05 Nov 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FORXIGA APPROVED IN THE EU FOR HEART FAILURE |
05 Nov 2020 |
05 Nov 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
LYNPARZA APPROVED IN THE EU AS 1ST-LINE MAINTENANCE TREATMENT WITH BEVACIZUMAB F |
05 Nov 2020 |
05 Nov 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
LYNPARZAAPPROVED IN THE EU FOR THE TREATMENT OF BRCA- MUTATED METASTATIC CASTRAT |
05 Nov 2020 |
05 Nov 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
02 Nov 2020 |
02 Nov 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ATACAND TO BE DIVESTED TO CHEPLAPHARM IN MORE THAN 70 COUNTRIES |
30 Oct 2020 |
30 Oct 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTORATE CHANGE |
29 Oct 2020 |
29 Oct 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ENHERTU GRANTED PRIORITY REVIEW IN THE US FOR THE TREATMENT OF HER2-POSITIVE MET |
28 Oct 2020 |
28 Oct 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FORXIGA CARDIOVASCULAR OUTCOMES BENEFIT APPROVED IN CHINA |
28 Oct 2020 |
28 Oct 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TAGRISSO ADJUVANT LUNG CANCER US PRIORITY REVIEW |
20 Oct 2020 |
20 Oct 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FORXIGA HF RECEIVES POSITIVE CHMP OPINION |
19 Oct 2020 |
19 Oct 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TRIXEO AEROSPHERE RECEIVES POSITIVE CHMP OPINION |
19 Oct 2020 |
19 Oct 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
COVID-19 ANTIBODIES ADVANCE AND GET US FUNDING |
13 Oct 2020 |
13 Oct 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FARXIGA GRANTED US BTD IN CHRONIC KIDNEY DISEASE |
02 Oct 2020 |
02 Oct 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Oct 2020 |
01 Oct 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTORATE CHANGE |
25 Sep 2020 |
25 Sep 2020 |
001-11960 |
| CERT |
Open Document
|
Open Filing |
|
24 Sep 2020 |
|
001-11960 |
| 8-A12B |
Open Document
|
Open Filing |
8-A12B |
24 Sep 2020 |
|
001-11960 |
| 25 |
Open Document
|
Open Filing |
25 |
24 Sep 2020 |
|
001-11960 |
| 6-K |
Open Document
|
Open Filing |
LYNPARZA RECOMMENDED FOR APPROVAL IN THE EU BY CHMP FOR BRCA-MUTATED METASTATIC |
21 Sep 2020 |
21 Sep 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
LYNPARZARECOMMENDED FOR APPROVAL IN EU BY CHMP AS 1ST-LINE MAINTENANCE TREATMENT |
21 Sep 2020 |
21 Sep 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TAGRISSO REDUCED THE RISK OF DISEASE RECURRENCE IN THE BRAIN BY 82% IN THE ADJUV |
21 Sep 2020 |
21 Sep 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA TO LIST US ADR EQUITY AND ALL US DEBT SECURITIES ON NASDAQ |
10 Sep 2020 |
10 Sep 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FASENRA MET BOTH CO-PRIMARY ENDPOINTS OF REDUCED NASAL POLYP SIZE AND BLOCKAGE I |
10 Sep 2020 |
10 Sep 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Sep 2020 |
01 Sep 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
IMFINZI APPROVED IN EU FOR SMALL CELL LUNG CANCER |
01 Sep 2020 |
01 Sep 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FARXIGA REDUCES CKD PROGRESSION AND RISK OF DEATH |
01 Sep 2020 |
01 Sep 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
PHASE I CLINICAL TRIAL INITIATED FOR MONOCLONAL ANTIBODY COMBINATION FOR THE PRE |
25 Aug 2020 |
25 Aug 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
IMFINZI APPROVED IN JAPAN FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG C |
21 Aug 2020 |
21 Aug 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
IMFINZI GRANTED FDA PRIORITY REVIEW FOR LESS-FREQUENT, FIXED-DOSE USE |
18 Aug 2020 |
18 Aug 2020 |
001-11960 |
| CERT |
Open Document
|
Open Filing |
NYSE CERTIFICATION |
12 Aug 2020 |
|
001-11960 |
| 8-A12B |
Open Document
|
Open Filing |
FORM 8-A12B |
06 Aug 2020 |
|
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FORM 6-K |
06 Aug 2020 |
06 Aug 2020 |
001-11960 |
| 424B2 |
Open Document
|
Open Filing |
FORM 424B2 |
05 Aug 2020 |
|
333-234586 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA PRICES A $3BN BOND ISSUE |
04 Aug 2020 |
04 Aug 2020 |
001-11960 |
| FWP |
Open Document
|
Open Filing |
FORM FWP |
04 Aug 2020 |
|
333-234586 |
| S-8 |
Open Document
|
Open Filing |
S-8 |
03 Aug 2020 |
|
333-240298 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
03 Aug 2020 |
03 Aug 2020 |
001-11960 |
| FWP |
Open Document
|
Open Filing |
FORM FWP |
03 Aug 2020 |
|
333-234586 |
| 424B2 |
Open Document
|
Open Filing |
FORM 424B2 |
03 Aug 2020 |
|
333-234586 |
| 6-K/A |
Open Document
| Data
|
Open Filing |
6-K/A |
31 Jul 2020 |
30 Jun 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
AZN: H1 2020 RESULTS |
30 Jul 2020 |
30 Jul 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TAGRISSO US BTD FOR EGFRM ADJUVANT LUNG CANCER |
30 Jul 2020 |
30 Jul 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
BOARD COMMITTEE CHANGES |
29 Jul 2020 |
29 Jul 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FARXIGA DAPA-CKD TRIAL MET ALL ENDPOINTS |
28 Jul 2020 |
28 Jul 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
IMFINZI RECOMMENDED FOR EU APPROVAL IN SCLC |
27 Jul 2020 |
27 Jul 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
CALQUENCE RECEIVES POSITIVE CHMP OPINION FOR CLL |
27 Jul 2020 |
27 Jul 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA ENTERS COLLABORATION IN ONCOLOGY |
27 Jul 2020 |
27 Jul 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
BREZTRI AEROSPHERE APPROVED IN THE US FOR THE MAINTENANCE TREATMENT OF COPD |
24 Jul 2020 |
24 Jul 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
HOLDING(S) IN COMPANY |
22 Jul 2020 |
22 Jul 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
HOLDING(S) IN COMPANY |
22 Jul 2020 |
22 Jul 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
HOLDING(S) IN COMPANY |
21 Jul 2020 |
21 Jul 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
HOLDING(S) IN COMPANY |
21 Jul 2020 |
21 Jul 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
COVID-19 VACCINE AZD1222 SHOWED ROBUST IMMUNE RESPONSES IN ALL PARTICIPANTS IN P |
20 Jul 2020 |
20 Jul 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR DECLARATION |
16 Jul 2020 |
16 Jul 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
BRILINTA GRANTED US FDA PRIORITY REVIEW FOR STROKE |
09 Jul 2020 |
09 Jul 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
LYNPARZA APPROVED IN THE EU FOR BRCA- MUTATED METASTATIC PANCREATIC CANCER |
08 Jul 2020 |
08 Jul 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Jul 2020 |
01 Jul 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
30 Jun 2020 |
30 Jun 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
SELUMETINIB GRANTED ORPHAN DRUG DESIGNATION IN JAPAN FOR NEUROFIBROMATOSIS TYPE |
30 Jun 2020 |
30 Jun 2020 |
001-11960 |
| 11-K |
Open Document
|
Open Filing |
|
26 Jun 2020 |
31 Dec 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
HOLDING(S) IN COMPANY |
17 Jun 2020 |
17 Jun 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
HOLDING(S) IN COMPANY |
17 Jun 2020 |
17 Jun 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA TO SUPPLY EUROPE WITH UP TO 400 MILLION DOSES OF OXFORD UNIVERSITY'S |
15 Jun 2020 |
15 Jun 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
EMTN PROGRAMME ROUTINE TECHNICAL UPDATE: PUBLICATION OF PROSPECTUS |
11 Jun 2020 |
11 Jun 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Jun 2020 |
01 Jun 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
BLOCK LISTING INTERIM REVIEW |
01 Jun 2020 |
01 Jun 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
LYNPARZA RECOMMENDED FOR APPROVAL IN EU BY CHMP FOR BRCA-MUTATED METASTATIC PANC |
01 Jun 2020 |
01 Jun 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
BRILINTA APPROVED IN THE US TO REDUCE THE RISK OF A FIRST HEART ATTACK OR STROKE |
01 Jun 2020 |
01 Jun 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ENHERTUSIGNIFICANTLY IMPROVED TUMOUR RESPONSE RATE AND OVERALL SURVIVAL IN HER2- |
29 May 2020 |
29 May 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
IMFINZI SHOWED A SUSTAINED OVERALL SURVIVAL BENEFIT IN 1ST-LINE EXTENSIVE-STAGE |
29 May 2020 |
29 May 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TAGRISSO DEMONSTRATED UNPRECEDENTED DISEASE-FREE SURVIVAL IN THE ADJUVANT TREATM |
29 May 2020 |
29 May 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
26 May 2020 |
26 May 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ENHERTU GRANTED ORPHAN DRUG DESIGNATION IN THE US FOR GASTRIC CANCER |
22 May 2020 |
22 May 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA ADVANCES RESPONSE TO GLOBAL COVID-19 CHALLENGE AS IT RECEIVES FIRST |
21 May 2020 |
21 May 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
LYNPARZA APPROVED IN THE US FOR HRR GENE-MUTATED METASTATIC CASTRATION-RESISTANT |
20 May 2020 |
20 May 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ENHERTU US BREAKTHROUGH STATUS FOR LUNG CANCER |
18 May 2020 |
18 May 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
BEVESPI AEROSPHERE APPROVED IN CHINA FOR COPD |
18 May 2020 |
18 May 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ENHERTU GRANTED BREAKTHROUGH THERAPY DESIGNATION IN THE US FOR HER2-POSITIVE MET |
11 May 2020 |
11 May 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA RECOVERY OF GLOBAL RIGHTS TO BRAZIKUMAB (MEDI2070) FROM ALLERGAN COM |
11 May 2020 |
11 May 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
LYNPARZA APPROVED IN THE US AS 1ST-LINE MAINTENANCE TREATMENT WITH BEVACIZUMAB F |
11 May 2020 |
11 May 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FARXIGA APPROVED IN THE US FOR THE TREATMENT OF HEART FAILURE IN PATIENTS WITH H |
06 May 2020 |
06 May 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 May 2020 |
01 May 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
RESULT OF AGM |
29 Apr 2020 |
29 Apr 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
AZN: FIRST-QUARTER 2020 RESULTS |
29 Apr 2020 |
29 Apr 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
LYNPARZA DEMONSTRATED OVERALL SURVIVAL BENEFIT IN PHASE III PROFOUND TRIAL FOR B |
24 Apr 2020 |
24 Apr 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
CHANGES TO ARRANGEMENTS FOR ANNUAL GENERAL MEETING |
17 Apr 2020 |
17 Apr 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
KOSELUGO (SELUMETINIB) APPROVED IN US FOR PAEDIATRIC PATIENTS WITH NEUROFIBROMAT |
14 Apr 2020 |
14 Apr 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TAGRISSO PHASE III ADAURA TRIAL WILL BE UNBLINDED EARLY AFTER OVERWHELMING EFFIC |
14 Apr 2020 |
14 Apr 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA DIVESTMENT OF MOVANTIK TO REDHILL BIOPHARMA COMPLETED |
02 Apr 2020 |
02 Apr 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Apr 2020 |
01 Apr 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
31 Mar 2020 |
31 Mar 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FARXIGA PHASE III DAPA-CKD TRIAL WILL BE STOPPED EARLY AFTER OVERWHELMING EFFICA |
30 Mar 2020 |
30 Mar 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
IMFINZI APPROVED IN THE US FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER |
30 Mar 2020 |
30 Mar 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
26 Mar 2020 |
26 Mar 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
LOKELMA APPROVED IN JAPAN FOR THE TREATMENT OF HYPERKALAEMIA |
26 Mar 2020 |
26 Mar 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
20 Mar 2020 |
20 Mar 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
LYNPARZA GRANTED ORPHAN DRUG DESIGNATION IN JAPAN FOR BRCA-MUTATED METASTATIC PA |
19 Mar 2020 |
19 Mar 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
IMFINZI CONFIRMED A SUSTAINED OVERALL SURVIVAL BENEFIT IN FINAL ANALYSIS OF THE |
17 Mar 2020 |
17 Mar 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
6-K |
12 Mar 2020 |
12 Mar 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
NOTICE OF AGM |
12 Mar 2020 |
12 Mar 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
UPDATE ON PHASE III GY004 TRIAL FOR CEDIRANIB ADDED TO LYNPARZA IN PLATINUM-SENS |
12 Mar 2020 |
12 Mar 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
10 Mar 2020 |
10 Mar 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
UPDATE ON PHASE III DANUBE TRIAL FOR IMFINZI AND TREMELIMUMAB IN UNRESECTABLE, S |
06 Mar 2020 |
06 Mar 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FILING OF FORM 20-F WITH SEC |
04 Mar 2020 |
04 Mar 2020 |
001-11960 |
| IRANNOTICE |
Open Document
|
Open Filing |
IRANNOTICE |
03 Mar 2020 |
|
001-11960 |
| 20-F |
Open Document
| Data
|
Open Filing |
20-F |
03 Mar 2020 |
31 Dec 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ANNUAL FINANCIAL REPORT |
03 Mar 2020 |
03 Mar 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
02 Mar 2020 |
02 Mar 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA COMPLETES DIVESTMENT AGREEMENT WITH ATNAHS PHARMA FOR ESTABLISHED HY |
02 Mar 2020 |
02 Mar 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
27 Feb 2020 |
27 Feb 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA DIVESTS GLOBAL RIGHTS TO MOVANTIK |
25 Feb 2020 |
25 Feb 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
19 Feb 2020 |
19 Feb 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
AZN: FULL-YEAR AND Q4 2019 RESULTS |
14 Feb 2020 |
14 Feb 2020 |
001-11960 |
| 4 |
Open Document
|
Open Filing |
4 |
07 Feb 2020 |
19 Dec 2019 |
001-35112 |
| 3 |
Open Document
|
Open Filing |
3 |
07 Feb 2020 |
19 Dec 2019 |
001-35112 |
| SC 13D |
Open Document
|
Open Filing |
SC 13D |
07 Feb 2020 |
|
|
| EFFECT |
Open Document
|
Open Filing |
|
06 Feb 2020 |
|
333-236014 |
| SC 13G/A |
Open Document
|
Open Filing |
|
05 Feb 2020 |
|
005-55247 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
03 Feb 2020 |
03 Feb 2020 |
001-11960 |
| SC 13G |
Open Document
|
Open Filing |
SC 13G |
30 Jan 2020 |
|
|
| SC 13G/A |
Open Document
|
Open Filing |
SEC SCHEDULE 13G |
27 Jan 2020 |
|
005-55247 |
| 6-K |
Open Document
|
Open Filing |
PHASE II DESTINY-GASTRIC01 TRIAL OF ENHERTU VERSUS CHEMOTHERAPY MET PRIMARY ENDP |
27 Jan 2020 |
27 Jan 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA TO RECOVER THE GLOBAL RIGHTS TO BRAZIKUMAB (MEDI2070) FROM ALLERGAN |
27 Jan 2020 |
27 Jan 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
BRILINTA MET PRIMARY ENDPOINT IN PHASE III THALES TRIAL IN STROKE |
27 Jan 2020 |
27 Jan 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA DIVESTS RIGHTS TO ESTABLISHED HYPERTENSION MEDICINES |
27 Jan 2020 |
27 Jan 2020 |
001-11960 |
| F-6 |
Open Document
|
Open Filing |
FORM F-6 |
22 Jan 2020 |
|
333-236014 |
| 6-K |
Open Document
|
Open Filing |
LYNPARZA REGULATORY SUBMISSION GRANTED PRIORITY REVIEW IN THE US FOR HRR-MUTATED |
21 Jan 2020 |
20 Jan 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
IMFINZI AND TREMELIMUMAB GRANTED ORPHAN DRUG DESIGNATION IN THE US FOR LIVER CAN |
21 Jan 2020 |
20 Jan 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
LYNPARZA REGULATORY SUBMISSION GRANTED PRIORITY REVIEW IN THE US FOR 1ST-LINE MA |
13 Jan 2020 |
13 Jan 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
UPDATE ON PHASE III STRENGTH TRIAL FOR EPANOVA IN MIXED DYSLIPIDAEMIA |
13 Jan 2020 |
13 Jan 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
LOKELMA APPROVED IN CHINA FOR THE TREATMENT OF ADULT PATIENTS WITH HYPERKALAEMIA |
06 Jan 2020 |
06 Jan 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FARXIGA GRANTED FDA PRIORITY REVIEW FOR PATIENTS WITH HEART FAILURE WITH REDUCED |
06 Jan 2020 |
06 Jan 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
02 Jan 2020 |
02 Jan 2020 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
LYNPARZAAPPROVED IN THE US AS A 1ST-LINE MAINTENANCE TREATMENT OF GERMLINE BRCA- |
30 Dec 2019 |
30 Dec 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA'S TRIPLE-COMBINATION THERAPY APPROVED IN CHINA FOR PATIENTS WITH COP |
23 Dec 2019 |
23 Dec 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ENHERTU (TRASTUZUMAB DERUXTECAN) APPROVED IN THE US FOR HER2-POSITIVE UNRESECTAB |
23 Dec 2019 |
23 Dec 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA DIVESTS RIGHTS TO ARIMIDEX AND CASODEX IN EUROPE AND CERTAIN ADDITIO |
20 Dec 2019 |
20 Dec 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FDA PANEL BACKS LYNPARZA USE FOR PANCREATIC CANCER |
17 Dec 2019 |
17 Dec 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
SEROQUEL RIGHTS AGREEMENT COMPLETE: EUROPE, RUSSIA |
16 Dec 2019 |
16 Dec 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
IMFINZI APPROVED IN CHINA FOR THE TREATMENT OF UNRESECTABLE, STAGE III NON-SMALL |
12 Dec 2019 |
12 Dec 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TRASTUZUMAB DERUXTECAN ACHIEVED A TUMOUR RESPONSE RATE OF 60.9% IN PIVOTAL PHASE |
11 Dec 2019 |
11 Dec 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
LYNPARZA APPROVED IN CHINA AS A 1ST-LINE MAINTENANCE THERAPY IN BRCA-MUTATED ADV |
05 Dec 2019 |
05 Dec 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA DIVESTS RIGHTS TO SEROQUEL AND SEROQUEL XR IN THE US AND CANADA |
03 Dec 2019 |
03 Dec 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
BLOCK LISTING INTERIM REVIEW |
02 Dec 2019 |
02 Dec 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
02 Dec 2019 |
02 Dec 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
IMFINZI GRANTED FDA PRIORITY REVIEW FOR THE TREATMENT OF PATIENTS WITH EXTENSIVE |
29 Nov 2019 |
29 Nov 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
CALQUENCE APPROVED IN THE US FOR ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEM |
21 Nov 2019 |
21 Nov 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
QTRILMET APPROVED IN THE EU FOR TREATMENT OF T2D |
15 Nov 2019 |
15 Nov 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FDA ACCEPTS REGULATORY SUBMISSION FOR SELUMETINIB |
14 Nov 2019 |
14 Nov 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ANIFROLUMAB DEMONSTRATED SUPERIORITY ACROSS MULTIPLE EFFICACY ENDPOINTS IN PATIE |
12 Nov 2019 |
12 Nov 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ROXADUSTAT PHASE III PROGRAMME POOLED ANALYSES SHOWED POSITIVE EFFICACY AND NO I |
12 Nov 2019 |
12 Nov 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ROXADUSTAT SIGNIFICANTLY INCREASED HAEMOGLOBIN LEVELS FOR CHRONIC KIDNEY DISEASE |
08 Nov 2019 |
08 Nov 2019 |
001-11960 |
| F-3ASR |
Open Document
|
Open Filing |
FORM F-3ASR |
08 Nov 2019 |
|
333-234586 |
| 6-K |
Open Document
|
Open Filing |
CALQUENCE DATA TO SHOW IMPROVED PROGRESSION-FREE SURVIVAL IN PHASE III FRONT-LIN |
06 Nov 2019 |
06 Nov 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Nov 2019 |
01 Nov 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA DIVESTS RIGHTS TO SEROQUEL AND SEROQUEL XR IN EUROPE AND RUSSIA |
30 Oct 2019 |
30 Oct 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
IMFINZI AND IMFINZI PLUS TREMELIMUMAB DELAYED |
28 Oct 2019 |
28 Oct 2019 |
001-11960 |
| SC 13D |
Open Document
|
Open Filing |
SC 13D |
25 Oct 2019 |
|
|
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA YEAR-TO-DATE AND Q3 2019 RESULTS |
24 Oct 2019 |
24 Oct 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FARXIGA APPROVED IN THE US TO REDUCE THE RISK OF HOSPITALISATION FOR HEART FAILU |
21 Oct 2019 |
21 Oct 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TRASTUZUMAB DERUXTECAN GRANTED FDA PRIORITY REVIEW FOR TREATMENT OF PATIENTS WIT |
17 Oct 2019 |
17 Oct 2019 |
001-11960 |
| 4 |
Open Document
|
Open Filing |
FORM 4 SUBMISSION |
09 Oct 2019 |
07 Oct 2019 |
001-39067 |
| 3/A |
Open Document
|
Open Filing |
FORM 3/A SUBMISSION |
09 Oct 2019 |
02 Oct 2019 |
001-39067 |
| 6-K |
Open Document
|
Open Filing |
HOLDING(S) IN COMPANY |
04 Oct 2019 |
04 Oct 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
HOLDING(S) IN COMPANY |
04 Oct 2019 |
04 Oct 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FASENRA APPROVED IN THE US FOR SELF-ADMINISTRATION |
04 Oct 2019 |
04 Oct 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR DECLARATION |
03 Oct 2019 |
03 Oct 2019 |
001-11960 |
| 3 |
Open Document
|
Open Filing |
FORM 3 SUBMISSION |
02 Oct 2019 |
02 Oct 2019 |
001-39067 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Oct 2019 |
01 Oct 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA DIVESTS RIGHTS FOR LOSEC TO CHEPLAPHAR |
01 Oct 2019 |
01 Oct 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
UPDATE ON US REGULATORY REVIEW OF PT010 IN COPD |
01 Oct 2019 |
01 Oct 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
LYNPARZA MORE THAN DOUBLED THE TIME WITHOUT RADIOGRAPHIC DISEASE PROGRESSION IN |
30 Sep 2019 |
30 Sep 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
LYNPARZA IMPROVED THE TIME WOMEN LIVED WITHOUT DISEASE PROGRESSION TO 22 MONTHS |
30 Sep 2019 |
30 Sep 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TAGRISSO IS THE ONLY 1ST-LINE TREATMENT FOR EGFR-MUTATED NON-SMALL CELL LUNG CAN |
30 Sep 2019 |
30 Sep 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
QTRILMET RECOMMENDED FOR APPROVAL IN EU BY CHMP |
23 Sep 2019 |
23 Sep 2019 |
001-11960 |
| 25-NSE |
Open Document
|
Open Filing |
|
18 Sep 2019 |
|
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA AMENDS COLLABORATION WITH IRONWOOD FOR LINZESS IN CHINA |
18 Sep 2019 |
18 Sep 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
IMFINZI IS FIRST IMMUNOTHERAPY TO SHOW BOTH SIGNIFICANT SURVIVAL BENEFIT AND IMP |
09 Sep 2019 |
09 Sep 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TAGRISSO APPROVED IN CHINA AS A 1ST-LINE TREATMENT FOR EGFR-MUTATED NON-SMALL CE |
04 Sep 2019 |
04 Sep 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
03 Sep 2019 |
03 Sep 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DETAILED RESULTS FROM PHASE III DAPA-HF TRIAL SHOWED FARXIGA SIGNIFICANTLY REDUC |
03 Sep 2019 |
03 Sep 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
BRILINTA REDUCED THE RISK OF CARDIOVASCULAR EVENTS IN PATIENTS WITH CORONARY ART |
03 Sep 2019 |
03 Sep 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ANIFROLUMAB PHASE III TRIAL MEETS PRIMARY ENDPOINT IN SYSTEMIC LUPUS ERYTHEMATOS |
29 Aug 2019 |
29 Aug 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
BREZTRI AEROSPHERE PHASE III ETHOS TRIAL MET ITS PRIMARY ENDPOINT IN CHRONIC OBS |
28 Aug 2019 |
28 Aug 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FASENRA GRANTED US ORPHAN DRUG DESIGNATION FOR EOSINOPHILIC OESOPHAGITIS |
28 Aug 2019 |
28 Aug 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ROXADUSTAT APPROVED IN CHINA FOR THE TREATMENT OF ANAEMIA IN NON-DIALYSIS-DEPEND |
22 Aug 2019 |
22 Aug 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA AGREES TO BUY US FDA PRIORITY REVIEW |
22 Aug 2019 |
22 Aug 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
UPDATE ON THE PHASE III NEPTUNE TRIAL |
21 Aug 2019 |
21 Aug 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FARXIGA MET PRIMARY ENDPOINT IN LANDMARK PHASE III |
20 Aug 2019 |
20 Aug 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTORATE CHANGE |
19 Aug 2019 |
19 Aug 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
CALQUENCE GRANTED US BREAKTHROUGH THERAPY DESIGNATION |
14 Aug 2019 |
14 Aug 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
LYNPARZA PHASE III PAOLA-1 TRIAL MET PRIMARY ENDPOINT |
14 Aug 2019 |
14 Aug 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TAGRISSO SIGNIFICANTLY IMPROVES OVERALL SURVIVAL |
09 Aug 2019 |
09 Aug 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
LYNPARZA PHASE III PROFOUND TRIAL IN HRR* |
07 Aug 2019 |
07 Aug 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FORXIGA LABEL UPDATED IN THE EU IN TYPE-2 DIABETES |
05 Aug 2019 |
05 Aug 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Aug 2019 |
01 Aug 2019 |
001-11960 |
| 6-K |
Open Document
| Data
|
Open Filing |
6-K |
25 Jul 2019 |
30 Jun 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
UPDATE ON US REGULATORY DECISION FOR FARXIGA |
15 Jul 2019 |
15 Jul 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
IMFINZI GRANTED US ORPHAN DRUG DESIGNATION FOR SMALL CELL LUNG CANCER |
12 Jul 2019 |
12 Jul 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FASENRA RECEIVES POSITIVE EU CHMP OPINION FOR SELF |
01 Jul 2019 |
01 Jul 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Jul 2019 |
01 Jul 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FORXIGA RECEIVES POSITIVE EU CHMP OPINION FOR |
01 Jul 2019 |
01 Jul 2019 |
001-11960 |
| 11-K |
Open Document
|
Open Filing |
|
27 Jun 2019 |
31 Dec 2018 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
IMFINZI IMPROVES OVERALL SURVIVAL AT INTERIM |
27 Jun 2019 |
27 Jun 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
BREZTRI AEROSPHERE (PT010) APPROVED IN JAPAN FOR PATIENTS WITH CHRONIC OBSTRUCTI |
19 Jun 2019 |
19 Jun 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
LYNPARZA APPROVED IN JAPAN FOR 1ST-LINE MAINTENANCE THERAPY IN BRCA-MUTATED ADVA |
19 Jun 2019 |
19 Jun 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
BEVESPI AEROSPHERE APPROVED BY THE JAPANESE MINISTRY OF HEALTH, LABOUR AND WELFA |
19 Jun 2019 |
19 Jun 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
LYNPARZA APPROVED IN THE EU FOR 1ST-LINE |
18 Jun 2019 |
18 Jun 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
CALQUENCE SIGNIFICANTLY PROLONGED THE TIME PATIENT |
17 Jun 2019 |
17 Jun 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
PUBLICATION OF A PROSPECTUS |
12 Jun 2019 |
12 Jun 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
CALQUENCE PHASE III ELEVATE-TN TRIAL MET PRIMARY |
06 Jun 2019 |
06 Jun 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
BLOCK LISTING INTERIM REVIEW |
03 Jun 2019 |
03 Jun 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
03 Jun 2019 |
03 Jun 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
LYNPARZA NEARLY DOUBLED THE TIME PATIENTS LIVED WITHOUT DISEASE PROGRESSION FROM |
03 Jun 2019 |
03 Jun 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
POOLED ANALYSES OF THE ROXADUSTAT GLOBAL PHASE III |
10 May 2019 |
10 May 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
08 May 2019 |
08 May 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR DECLARATION |
08 May 2019 |
08 May 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TRASTUZUMAB DERUXTECAN DEMONSTRATED CLINICALLY |
08 May 2019 |
08 May 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
CALQUENCE PHIII ASCEND TRIAL MET PRIMARY ENDPOINT |
07 May 2019 |
07 May 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
QTERNMET XR APPROVED IN THE US FOR TYPE-2 DIABETES |
03 May 2019 |
03 May 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 May 2019 |
01 May 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
01 May 2019 |
01 May 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
LYNPARZA RECEIVES POSITIVE EU CHMP OPINION FOR 1ST |
29 Apr 2019 |
29 Apr 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
RESULT OF AGM |
26 Apr 2019 |
26 Apr 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
AZN: Q1 2019 RESULTS |
26 Apr 2019 |
26 Apr 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
LYNPARZA APPROVED IN EU FOR THE TREATMENT OF GERMLINE BRCA-MUTATED HER2-NEGATIVE |
10 Apr 2019 |
10 Apr 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
HOLDING(S) IN COMPANY |
04 Apr 2019 |
04 Apr 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
03 Apr 2019 |
03 Apr 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
02 Apr 2019 |
02 Apr 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Apr 2019 |
01 Apr 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
SELUMETINIB GETS BREAKTHROUGH THERAPY DESIGNATION |
01 Apr 2019 |
01 Apr 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
RESULTS OF PLACING |
29 Mar 2019 |
29 Mar 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
AZ AND DAIICHI SANKYO ENTER COLLABORATION IN NOVEL |
29 Mar 2019 |
29 Mar 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FORXIGA APPROVED IN JAPAN FOR TYPE-1 DIABETES |
27 Mar 2019 |
27 Mar 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FORXIGA APPROVED IN EUROPE FOR TYPE-1 DIABETES |
25 Mar 2019 |
25 Mar 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
US FDA GRANTS SARACATINIB ODD FOR IPF |
18 Mar 2019 |
18 Mar 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
NOTICE OF AGM |
14 Mar 2019 |
14 Mar 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
6-K |
14 Mar 2019 |
14 Mar 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
12 Mar 2019 |
12 Mar 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FILING OF FORM 20-F WITH SEC |
06 Mar 2019 |
06 Mar 2019 |
001-11960 |
| IRANNOTICE |
Open Document
|
Open Filing |
IRANNOTICE |
05 Mar 2019 |
|
001-11960 |
| 20-F |
Open Document
| Data
|
Open Filing |
20-F |
05 Mar 2019 |
31 Dec 2018 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ANNUAL FINANCIAL REPORT |
05 Mar 2019 |
05 Mar 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Mar 2019 |
01 Mar 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
LYNPARZA RECEIVES POSITIVE EU CHMP OPINION |
01 Mar 2019 |
01 Mar 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
LYNPARZA SIGNIFICANTLY DELAYED DISEASE PROGRESSION |
26 Feb 2019 |
26 Feb 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
BRILINTA'S PHIII THEMIS TRIAL MET PRIMARY ENDPOINT |
25 Feb 2019 |
25 Feb 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA FULL-YEAR AND Q4 2018 RESULTS |
14 Feb 2019 |
14 Feb 2019 |
001-11960 |
| SC 13G/A |
Open Document
|
Open Filing |
SEC SCHEDULE 13G |
12 Feb 2019 |
|
005-55247 |
| 6-K |
Open Document
|
Open Filing |
US FDA GRANTS FASENRA ORPHAN DRUG DESIGNATION |
06 Feb 2019 |
06 Feb 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
US FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION |
05 Feb 2019 |
05 Feb 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
EMA GRANTS PRIME ELIGIBILITY FOR MEDI8897 |
05 Feb 2019 |
05 Feb 2019 |
001-11960 |
| SC 13G/A |
Open Document
|
Open Filing |
|
04 Feb 2019 |
|
005-55247 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Feb 2019 |
01 Feb 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FORXIGA RECEIVES POSITIVE EU CHMP OPINION |
01 Feb 2019 |
01 Feb 2019 |
001-11960 |
| SC 13G |
Open Document
|
Open Filing |
SC 13G |
30 Jan 2019 |
|
|
| 6-K |
Open Document
|
Open Filing |
COMPLETION OF DIVESTMENT OF US SYNAGIS RIGHTS |
25 Jan 2019 |
25 Jan 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA ANNOUNCES ORGANISATIONAL CHANGES |
07 Jan 2019 |
07 Jan 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
02 Jan 2019 |
02 Jan 2019 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
BEVESPI AEROSPHERE APPROVED IN THE EU FOR COPD |
20 Dec 2018 |
20 Dec 2018 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
LYNPARZA MEETS PRIMARY ENDPOINT IN SOLO-3 TRIAL |
20 Dec 2018 |
20 Dec 2018 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
PHASE III ROCKIES AND OLYMPUS ROXADUSTAT TRIALS |
20 Dec 2018 |
20 Dec 2018 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FDA APPROVES LYNPARZA AS 1L MAINTENANCE THERAPY |
19 Dec 2018 |
19 Dec 2018 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ROXADUSTAT APPROVED IN CHINA FOR THE TREATMENT OF ANAEMIA IN CHRONIC KIDNEY DISE |
18 Dec 2018 |
18 Dec 2018 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTORATE CHANGE |
14 Dec 2018 |
14 Dec 2018 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
UPDATE ON THE PHASE III EAGLE TRIAL OF IMFINZI |
07 Dec 2018 |
07 Dec 2018 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIVESTMENT OF RIGHTS TO COVIS COMPLETED |
06 Dec 2018 |
06 Dec 2018 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
04 Dec 2018 |
04 Dec 2018 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
BLOCK LISTING INTERIM REVIEW |
03 Dec 2018 |
03 Dec 2018 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
03 Dec 2018 |
03 Dec 2018 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
GRUNENTHAL AGREEMENT FOR NEXIUM VIMOVO COMPLETED |
03 Dec 2018 |
03 Dec 2018 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
US FDA GRANTS FASENRA ODD FOR EGPA |
26 Nov 2018 |
26 Nov 2018 |
001-11960 |
| 25-NSE |
Open Document
|
Open Filing |
|
16 Nov 2018 |
|
001-11960 |
| 25-NSE |
Open Document
|
Open Filing |
|
16 Nov 2018 |
|
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA PROVIDES UPDATE ON PHASE III MYSTIC |
16 Nov 2018 |
16 Nov 2018 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA TO DIVEST US SYNAGIS RIGHTS TO SOBI |
13 Nov 2018 |
13 Nov 2018 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
US FDA ACCEPTS REGULATORY SUBMISSION FOR LYNPARZA |
13 Nov 2018 |
13 Nov 2018 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FARXIGA SIGNIFICANTLY REDUCED HOSPITALISATION FOR |
13 Nov 2018 |
13 Nov 2018 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
AZN: YEAR-TO-DATE AND Q3 2018 RESULTS |
08 Nov 2018 |
08 Nov 2018 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIVESTMENT OF RIGHTS TO COVIS PHARMA |
06 Nov 2018 |
06 Nov 2018 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Nov 2018 |
01 Nov 2018 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ADDITIONAL FINANCIAL INFORMATION-GRUNENTHAL DEAL |
31 Oct 2018 |
31 Oct 2018 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
GRUNENTHAL AGREEMENT FOR RIGHTS TO NEXIUM VIMOVO |
30 Oct 2018 |
30 Oct 2018 |
001-11960 |
| SC 13D |
Open Document
|
Open Filing |
SC 13D |
29 Oct 2018 |
|
|
| 4 |
Open Document
|
Open Filing |
FORM 4 SUBMISSION |
24 Oct 2018 |
22 Oct 2018 |
001-38697 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA EXTENDS INNATE PHARMA COLLABORATION |
23 Oct 2018 |
23 Oct 2018 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
LYNPARZA SHOWS 70% REDUCTION IN PFS OVARIAN CANCER |
22 Oct 2018 |
22 Oct 2018 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
CHMP POSITIVE OPINION BEVESPI AEROSPHERE |
19 Oct 2018 |
19 Oct 2018 |
001-11960 |
| 3 |
Open Document
|
Open Filing |
FORM 3 SUBMISSION |
17 Oct 2018 |
17 Oct 2018 |
001-38697 |
| 6-K |
Open Document
|
Open Filing |
FDA ORPHAN DRUG FOR LYNPARZA IN PANCREATIC CANCER |
16 Oct 2018 |
16 Oct 2018 |
001-11960 |
| SC 13D/A |
Open Document
|
Open Filing |
SC 13D/A |
12 Oct 2018 |
|
|
| SC 13D |
Open Document
|
Open Filing |
SC 13D |
05 Oct 2018 |
|
|
| 4 |
Open Document
|
Open Filing |
FORM 4 SUBMISSION |
02 Oct 2018 |
28 Sep 2018 |
001-38670 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Oct 2018 |
01 Oct 2018 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ATACAND AGREEMENT WITH CHEPLAPHARM COMPLETED |
01 Oct 2018 |
01 Oct 2018 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
PREVIOUS ANNOUNCEMENT REGARDING APPOINTMENT OF NED |
28 Sep 2018 |
28 Sep 2018 |
001-11960 |
| 3 |
Open Document
|
Open Filing |
FORM 3 SUBMISSION |
25 Sep 2018 |
25 Sep 2018 |
001-38670 |
| 6-K |
Open Document
|
Open Filing |
OVERALL SURVIVAL DATA FOR IMFINZI: STAGE III NSCLC |
25 Sep 2018 |
25 Sep 2018 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
EMA APPROVES AZ'S IMFINZI FOR STAGE III NSCLC |
24 Sep 2018 |
24 Sep 2018 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FARXIGA GETS POSITIVE RESULT IN DECLARE-TIMI 58 |
24 Sep 2018 |
24 Sep 2018 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FDA APPROVES AZS LUMOXITI IN HAIRY CELL LEUKAEMIA |
14 Sep 2018 |
14 Sep 2018 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TEZEPELUMAB FDA BREAKTHROUGH THERAPY DESIGNATION |
07 Sep 2018 |
07 Sep 2018 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
DIRECTORATE CHANGE |
06 Sep 2018 |
06 Sep 2018 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
04 Sep 2018 |
04 Sep 2018 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA UPDATE ON ANIFROLUMAB IN SLE |
31 Aug 2018 |
31 Aug 2018 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
EC APPROVES BYDUREON BCISE DEVICE FOR T2 DIABETES |
30 Aug 2018 |
30 Aug 2018 |
001-11960 |
| CERT |
Open Document
|
Open Filing |
NYSE CERTIFICATION - ASTRAZENECA PLC |
23 Aug 2018 |
|
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA PIIIB TRIAL UPDATE FOR BEVESPI IN COPDASTRAZENECA PIIIB TRIAL UPDATE |
23 Aug 2018 |
23 Aug 2018 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
AZ'S TAGRISSO APPROVED IN JAPAN FOR 1ST-LINE NSCLC |
21 Aug 2018 |
21 Aug 2018 |
001-11960 |
| 8-A12B |
Open Document
|
Open Filing |
FORM 8-A12B |
17 Aug 2018 |
|
001-11960 |
| 6-K |
Open Document
|
Open Filing |
FORM 6-K |
17 Aug 2018 |
17 Aug 2018 |
001-11960 |
| 424B2 |
Open Document
|
Open Filing |
FORM 424B2 |
16 Aug 2018 |
|
333-214756 |
| 6-K |
Open Document
|
Open Filing |
ASTRAZENECA PRICES A $3BN BOND ISSUE |
15 Aug 2018 |
15 Aug 2018 |
001-11960 |
| FWP |
Open Document
|
Open Filing |
FORM FWP |
15 Aug 2018 |
|
333-214756 |
| S-8 |
Open Document
|
Open Filing |
S-8 |
14 Aug 2018 |
|
333-226830 |
| FWP |
Open Document
|
Open Filing |
FORM FWP |
14 Aug 2018 |
|
333-214756 |
| 424B2 |
Open Document
|
Open Filing |
FORM 424B2 |
14 Aug 2018 |
|
333-214756 |
| 6-K |
Open Document
|
Open Filing |
6-K |
10 Aug 2018 |
10 Aug 2018 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
EMA GRANTS OD FOR SELUMETINIB IN NF1 |
03 Aug 2018 |
03 Aug 2018 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Aug 2018 |
01 Aug 2018 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
CHMP RECOMMENDS IMFINZI FOR STAGE III NSCLC |
27 Jul 2018 |
27 Jul 2018 |
001-11960 |
| 6-K |
Open Document
| Data
|
Open Filing |
6-K |
26 Jul 2018 |
26 Jul 2018 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
ATACAND TO BE DIVESTED TO CHEPLAPHARM IN EUROPE |
24 Jul 2018 |
24 Jul 2018 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
HOLDING(S) IN COMPANY |
18 Jul 2018 |
18 Jul 2018 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
02 Jul 2018 |
02 Jul 2018 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
LYNPARZA APPROVED IN JAPAN FOR BRCAM BREAST CANCER |
02 Jul 2018 |
02 Jul 2018 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
IMFINZI APPROVED IN JAPAN FOR STAGE III NSCLC |
02 Jul 2018 |
02 Jul 2018 |
001-11960 |
| 11-K |
Open Document
|
Open Filing |
|
29 Jun 2018 |
31 Dec 2017 |
001-11960 |
| 6-K |
Open Document
|
Open Filing |
BYDUREON RECEIVES POSITIVE CHMP OPINION FOR BCISE |
29 Jun 2018 |
29 Jun 2018 |
001-11960 |